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NIRAV RAJIVKUMAR SHAH. Host factors controlling virus infection: implications for 
antivirals and virotherapy. (Under the direction of DR.VALERY GRDZELISHVILI) 
 
 
Viruses are obligate intracellular parasites rely heavily on host components and 
pathways for their replication. Studying different cellular factors affecting viral infection 
can enable us to identify novel drug targets, improve current antiviral treatments and 
improve efficacy of virus based therapies. This dissertation examines two prototypic 
members of an order Mononegavirales, vesicular stomatitis virus (VSV) and Sendai virus 
(SeV) and is focused on: 1) resistance of some hosts to a broad spectrum antiviral drug 
ribavirin and 2) resistance of some pancreatic cancers to oncolytic virotherapy.  Here, for 
the first time we examined whether certain cell types are naturally resistant to ribavirin 
even without prior drug exposure. Our results show striking differences between cell 
types in their response to ribavirin. Our data also suggest that this resistance was due to 
cellular factors rather than viral determinants and ribavirin may inhibit the same virus via 
different mechanisms in different cells depending on the ribavirin metabolism. 
Additionally, resistance of oncolytic VSV therapy in specific human pancreatic ductal 
adenocarcinoma (PDA) cells was investigated and this resistance was attributed to 
constitutive expression of the IFN-stimulated antiviral genes MxA and OAS. Decreasing 
the levels of MxA and OAS by inhibition of JAK/STAT signaling, improved VSV 
infection and oncolysis. Overall, our study demonstrated heterogeneity in the type I IFN 
signaling status of PDA cells and suggests MxA and OAS as potential biomarkers for 
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 Viruses are obligate intracellular parasites, rely heavily on host components and 
processes for their replication. Viruses are responsible for causing various human 
diseases. It has been estimated that different viral infections lead to ~3.5 million deaths 
annually worldwide (Krausslich and Bartenschlager 2009). RNA viruses are the most 
prevalent, and viruses such as Ebola and Marburg viruses (Paragas and Geisbert 2006), 
West Nile virus (Hayes and Gubler 2006), SARS (severe acute respiratory distress 
syndrome) coronavirus (Spicuzza, Spicuzza et al. 2007), Rift Valley fever virus (Flick 
and Bouloy 2005), Nipah and Hendra virus (Bossart and Broder 2006), hantaviruses 
(Sun, Chung et al. 2007), influenza virus (Severson, McDowell et al. 2008) can cause 
severe infectious and devastating diseases.  In addition to the importance of viruses as 
pathogens, many viruses have been exploited as vaccine vectors, gene therapy vectors or 
anti-cancer agents.  A detailed mechanistic understanding of viral replication cycle in 
different cell types is fundamental in developing reagents to prevent and combat viral 
diseases, and to exploit viruses in various health and technology applications. 
The viruses consist of genetic material either as DNA or RNA. The genetic 
material of all viruses is protected by a viral protein coat, known as a capsid. Many 
viruses also possess a lipid bilayer (known as a viral envelope) that contains viral and 
host proteins. Based on the type of viral genetic material and its replication mechanism, 
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viruses are classified into seven groups according to a system designed by David 
Baltimore (Baltimore 1971). In the David Baltimore classification system of viruses, 
Group I and Group II consist of double-stranded (ds) DNA and single-stranded (ss) DNA 
viruses respectively. Their replication cycle follows the central dogma of molecular 
biology (DNA genome is transcribed into mRNA which is translated into proteins). 
Group III, IV, and V are dsRNA, ssRNA(+), ssRNA(-) viruses, respectively. The 
ssRNA(+) viruses have an RNA genome on mRNA polarity and structure, and it can be 
directly translated to proteins. However, genome of ssRNA(-)  viruses and dsRNA must 
be transcribed first to synthesize translatable mRNAs before protein synthesis. Viruses of 
group VI are retroviruses, which first convert their RNA genome into DNA by reverse 
transcriptase. The viruses of group VII have dsDNA genome, but they utilize reverse 
transcriptase during their replication.   
My dissertation research focuses on ssRNA(-)  viruses, specifically those 
belonging to the non-segmented negative strand (NNS) RNA viruses. The ssRNA(-)   
include the families Rhabdoviridae, Paramyxoviridae, Filoviridae, Bornaviridae, 
Orthomyxoviridae, Bunyaviridae and Arenaviridae. First four families aggregate the 
order Mononegavirales (Table 1) and characterized by their non-segmented genome 
(Pringle 1999).  Unlike members of the order Mononegavirales, viruses belonging to the 
Orthomyxoviridae, Bunyaviridae and Arenaviridae families have genome segmented 





   
 
 
Table 1. Classification of viruses of the order Mononegavirales 
 
Adapted from (Pringle 1999) 
 
This dissertation focused on two prototypic members of the order 
Mononegavirales, vesicular stomatitis virus (VSV) and Sendai virus (SeV). This order 
includes many important plant, animal and human pathogens such as Ebola and Marburg 
viruses, Hendra, Nipah, mumps, measles, rabies and respiratory syncytial virus (RSV). A 
majority of current understanding of the molecular biology of Mononegavirales comes 
from widely studied prototypic models, VSV and SeV (Lamb and Parks 2007). VSV and 
SeV are both relatively weak human pathogens without any transforming properties; 
because both viruses replicate in cytoplasm and do not integrate their genomic material 
into host cellular DNA (Lawson, Stillman et al. 1995, Barber 2004). Moreover, 
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replication competent recombinant strains can be developed to accommodate relatively 
large gene inserts into their genome. Also, both VSV and SeV grow to high titers in vitro, 
which facilitate the purification with high yield. Both VSV and SeV are great models to 
study mechanisms of virus infection, antiviral drug resistance, vaccine vectors and 
oncolytic (anticancer) virus agents. 
Replication of viruses in a host cell depends on the interaction of many viral and 
cellular (“host”) factors. Studying specific host-viral interactions has important practical 
implications to develop effective antiviral treatments and effective viral vectors.  This 
dissertation focuses on two different aspects of host-viral interactions: (1) Mechanisms of 
resistance of the antiviral drug ribavirin on VSV and SeV; (2) To identify potential 
biomarkers for pancreatic ductal adenocarcinoma (PDA) resistance to oncolytic VSV to 
improve anticancer treatment efficacy. 
Although effective vaccines have been developed for many viral pathogens, it is 
more challenging to develop effective vaccines against many viruses due to high genome 
mutation frequency. Moreover, even though vaccines are effective as a prophylactic tool, 
they are generally not effective as a treatment post exposure. Although research from the 
past several decades resulted into the development of several antiviral drugs, to this day, 
only about 40 antiviral drugs have been developed and approved for different virus 
infections, a majority of them being against HIV infections (De Clercq 2004). An 
increasing number of drug resistant viral strains emphasize the urgent need to develop 
newer and more effective antiviral strategies to combat different viral infection (De 
Clercq 2004, Krausslich and Bartenschlager 2009). It is very difficult to develop antiviral 
drugs especially against viruses due to following reasons: (1) Viruses are heavily 
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dependent on host cellular pathways; (2) Viruses mutate rapidly compared to bacteria and 
develops rapid resistance to drug; (3) Most viruses have very few genes, hence few 
targets for the development of antiviral drugs. Furthermore, many patients do not respond 
to approved antiviral drugs treatments due to various host and viral factors such as insulin 
resistance, obesity, ethnicity, age, sex and viral genotypes (Asselah, Estrabaud et al. 
2010) . Thus, it is increasingly important to identify factors that can allow us to predict 
the response antiviral therapies. 
The goal of my first study was to determine the mechanism of resistance of 
certain cell types to the antiviral drug, ribavirin. This drug is the major antiviral treatment 
against hepatitis C virus (HCV) and some other clinically important human viruses. We 
found that specific cells can be naturally resistant to ribavirin treatment and specific 
cellular and not viral factors are responsible for this resistance. A broad spectrum 
antiviral drug, ribavirin in combination with IFN is a standard treatment for the patients 
with chronic HCV infection. However, this treatment is ineffective in ~45-50% of 
patients and these patients are called non-responders (Thomas, Feld et al. 2010). The 
mechanism of this non-responsiveness to ribavirin-IFN treatment is not completely 
understood.  Virus-based resistance to ribavirin via generation of virus mutants has been 
extensively studied. However, recent reports suggest that cell based resistance to ribavirin 
can be developed upon repeated exposure to the drug via decreased uptake. But natural 
resistance of cells to ribavirin (without prior exposure) has not been investigated. Here, 
we investigated the role of specific cellular and not viral factors in natural ribavirin 
resistance against two NNS RNA viruses VSV and SeV in several cell types. Since it is 
difficult to generate drug resistance against host factors, studying host factors interacting 
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with viral factors during infection will be extremely critical to understand drug resistance 
and to develop novel drugs targeting host factors. (Lederman 1995; Tan, Ganji et al. 
2007).   
In the second part of my dissertation, I focus on a relatively recent anti-cancer 
approach utilizing viruses to specifically target and kill tumor cells without infecting 
healthy cells. Viruses used in such anti-cancer therapy are known as oncolytic viruses 
(OVs). Many studies have demonstrated that viruses can be used successfully as 
anticancer agents. However, great variability in the susceptibility to OV infection was 
observed against various malignancies (Paglino and van den Pol 2011; Murphy, Besmer 
et al. 2012). Thus, better understanding of the host-viral interactions can be beneficial to 
improve virus mediated therapy (Schwegmann and Brombacher 2008; Moerdyk-
Schauwecker, Shah et al. 2012). Here we investigated the role of type I IFN signaling in 
oncolytic VSV resistance in PDA cells. The goal of my second study was to identify 
potential biomarkers associated with permissibility of human pancreatic cancer to 
oncolytic virotherapy using VSV and several other viruses. We were able to identify two 
potential biomarkers for oncolytic VSV infection resistance. Moreover, continuation of 
this project is presently underway which mainly focuses on NF-κB activation in cancer 







   
1.2 VSV and SeV as model RNA viruses 
VSV is an enveloped virus with a helical nucleocapsid containing single-stranded, 
negative-sense RNA with an elongated bullet-like shape.VSV is the prototypic widely-
studied member of the family Rhabdoviridae. A majority of knowledge about the 
replication of NNS RNA viruses has come from studying VSV (Lyles, 2007). VSV 
causes acute disease in livestock populations and is characterized by symptoms similar to 
foot-and-mouth disease virus including fever, vesicles in oral cavity and skin. Infection in 
humans by VSV is asymptomatic and laboratory-adapted strains are rarely pathogenic for 
humans (Letchworth, Rodriguez et al. 1999; Rodriguez 2002).  
Similar to VSV, SeV (mouse parainfluenza virus type 1) is a prototype of the 
family Paramyxoviridae of the order Mononegavirales. This family includes some of the 
most ubiquitous disease causing viruses to humans and animals including measles, 
respiratory syncytial virus (RSV), parainfluenza viruses, mumps virus, Hendra virus, 
Nipah virus, human metapneumovirus, Newcastle disease virus, canine distemper virus 
and rinderpest virus (Lamb, Paterson et al. 2006). Similar to VSV, SeV also contains 
NNS RNA genomes with negative polarity and replicate within the cytoplasm (Lamb, 
Paterson et al. 2006).  
The RNA genome of VSV is 11 to 12 kb, encapsidated by approximately 1,200 
copies of VSV nucleoprotein (N) (Green, Zhang et al. 2006). The nucleocapsid is also 
associated with virus encoded phosphoprotein (P) and polymerase protein (L) with lesser 
extent (Green, Macpherson et al. 2000).  L protein is mainly responsible for all of the 
enzymatic activities associated with the synthesis of both translatable and genetic RNA 
(Rahmeh, Schenk et al. 2010). Nucleocapsid is also associated with matrix (M) protein 
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which condenses the nucleocapsid into very tight nucleocapsid-matrix complex. VSV M 
also interacts with the lipid bilayer of virus envelop (Lenard and Vanderoef 1990; 
Swinteck and Lyles 2008). The VSV Glycoprotein (G) is responsible for enabling VSV 
to infect most of the mammalian cell types (Stanifer, Cureton et al. 2011). To date there 
has not been any specific cell surface receptor identified which is required by VSV G 
protein. Binding of VSV G to the cell surface occurs via negatively charged membrane 
lipids followed by actin and clathrin-dependent endocytosis (Cureton, Massol et al. 
2010). After the particle has been internalized acidification of endosomal membrane 
facilitates fusion of viral envelop, allowing the release of viral ribonucleoprotein core 
into cytoplasm (Stanifer, Cureton et al. 2011). 
 SeV is spherical virion that range in average diameter from 150 to 200 nm. The 
virion consists of a nucleocapsid (also known as ribonucleoprotein or RNP) tightly 
packaged in a lipid envelope which is acquired from host cell membrane during budding. 
The envelope contains spike like projections composed of Hemaglutinin Neuraminidase 
(HN) and Fusion (F) transmembrane glycoproteins. The envelope is surrounded by a 
nonglycosylated matrix (M) protein from inside (Lamb, Mahy et al. 1976; Lamb and 
Parks 2007). SeV also has a P/V/C gene which can code for seven different polypeptides 
(Lamb and Parks 2007). However, V and C proteins are not required by SeV for 
replication (Fukuhara N, Huang C et al. 2002; Kato, Cortese-Grogan et al. 2004/7). SeV 
also has the large L polymerase having the catalytic role in viral RNA synthesis 
(Smallwood, Hovel et al. 2002/12/5; Lamb and Parks 2007) SeV HN is required for the 
virus adsorption to the cell surface molecule containing sialic acid. HN is also responsible 
for the enzymatic cleavage of sialic acid from both the surfaces of virions and infected 
9 
   
cells. Moreover, it has been shown that HN promotes viral membrane to cell membrane 
fusion activity (Lamb, Paterson et al. 2006). SeV F protein mediates viral penetration by 
fusion between the virions envelope and the host cell plasma membrane and this fusion 
event occurs at neutral pH (Lamb 1993). Fusion leads to the delivery of viral 
nucleocapsid into the cytoplasm and the fusion of infected cells with neighboring cells to 
form syncytia (multi-nucleated giant cell formation) (Lamb 1993; Lamb and Parks 2007).  
Both VSV and SeV have served as excellent models to study fundamentals of 
virus pathogenesis, drug resistance and virotherapy. VSV can infect almost any 
vertebrate cells and have a short life cycle. Because of these advantages VSV has been 
used an excellent model virus to study virus entry, replication, and mechanisms of innate 
and adaptive immune response. The cell-free assays like in vitro transcription serve as a 
great tool to study virus transcription and replication (Horikami and Moyer 1995/8/20; 
Chen, Ogino et al. 2007).  
Studying the host-viral interactions can be benefited greatly, if viruses harboring 
specific mutations in their genome can be engineered, such system is known as reverse 
genetics. The biggest challenge with NNS RNA viruses was a lack of such system to 
manipulate the RNA genome with negative polarity. In early 1990s the first reverse 
genetic system was established for NNS RNA viruses using VSV and SeV (Garcin, Pelet 
et al. 1995; Lawson, Stillman et al. 1995; Whelan, Ball et al. 1995).  The reverse-genetics 
system is an extremely powerful tool to dissect the different aspects of NNS RNA 
genome replication and transcription (Whelan and Wertz 1999/1; Conzelmann 2004). 
VSV and SeV have also been used as vaccine vectors for several decades. Both VSV and 
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SeV have been shown to have promising results on animal models when used as vaccine 
vectors (Takimoto, Hurwitz et al. 2005; Mire, Miller et al. 2012). 
 Both VSV and SeV propagate rapidly in cell culture and infect various cell types 
from different sources, making them useful for the screening of different antiviral drugs 
and studying their mechanisms of action. Using reverse genetic approach recombinant 
VSV and SeV have been developed to facilitate the visualization of virus infection. These 
recombinant viruses replicate similarly to wt strains and utilize expression of fluorescent 
proteins to monitor infection.  This approach facilitates the study of the mechanism of 
action of any antiviral drugs with these recombinant viruses in different cell types. 
Moreover, VSV can replicate poorly in non-transformed normal cells but replicates 
efficiently in transformed cell lines. This observation was exploited to use VSV as an anti 
cancer agent in the past decade (Stojdl, Lichty et al. 2000; Balachandran, Porosnicu et al. 
2001; Giedlin, Cook et al. 2003; Obuchi M, Fernandez M et al. 2003; Barber 2004). 
Development of reverse genetic system have also provided a much better platform to 
synthesize highly specific, safe and effective recombinant oncolytic VSV for various type 
of cancers (Stojdl DF 2003; Barber 2004; Hastie and Grdzelishvili 2012).  
 
  
   
CHAPTER 2: CELL TYPE MEDIATED RESISTANCE OF VESICULAR 




Ribavirin: clinical importance. 
 Ribavirin (1-ß-D-ribofuranosyl-1,2,4-triazole-3-carboxamide): a nucleoside 
analog was first synthesized in 1972 (Sidwell, Huffman et al. 1972) and demonstrated its 
diverse antiviral activity against several RNA and DNA viruses (Crotty, Cameron et al. 
2001; Parker 2005; Vignuzzi, Stone et al. 2005; Dixit and Perelson 2006). Ribavirin was 
originally approved in humans to treat respiratory syncytial virus infection in children. 
Later it was approved for the treatment of Lassa fever virus infection (Dixit and Perelson 
2006). Most importantly to date ribavirin in combination with Interferon-α (IFN) is the 
most effective treatment available for HCV infection. ribavirin alone has a transient 
effect on HCV replication in patients (Thomas, Feld et al. 2010), however it dramatically 
improves the long term therapeutic response when treated in combination with IFN (Dixit 
and Perelson 2006; Thomas, Feld et al. 2010). It has been estimated that ~170 million 
people are living with HCV infection worldwide (Dixit and Perelson 2006). In ~70% of 
cases this infection becomes chronic and can lead to the development of cirrhosis, 
fibrosis and/or hepatocellular carcinoma (HCC) (Hoofnagle 2002; Dixit and Perelson 
2006). Many patients infected with HCV have demonstrated a long lasting effect of 
ribavirin-IFN therapy. However, a growing number of individuals infected with hepatitis 
C virus (HCV) fail to respond to therapy. Although it was thought that development of 
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agents targeting each steps of HCV infection cycle would make ribavirin-IFN therapy 
antiquated, newer studies indicate otherwise (Thomas, Feld et al. 2010). Antiviral drugs 
which directly targets to the viral life cycle are likely to generate resistant strains. 
Ribavirin-IFN therapy is required to achieve optimal response.  Moreover, recent clinical 
trials with HCV protease inhibitors have indicated that ribavirin therapy is required for 
the prevention of viral relapse (Shiffman 2009). Together these studies clearly suggest 
that studying the mechanisms of action of ribavirin and its resistance is a promising 
approach to improve the treatment options for HCV infection.   
Structure and metabolism of ribavirin. 
To understand the mechanism of action of any nucleoside analog, it is extremely 
important to study the metabolism at cellular and molecular levels (Parker 2005). 
Structurally ribavirin has no close resemblance to any natural nucleoside. However, the 
triazole ring is attached to the ribose sugar making ribavirin resembles to ribonucleoside 
and not the deoxyribonucleoside (Sidwell, Huffman et al. 1972). Once transported, 
ribavirin metabolizes in the cell by the enzymes involved in purine metabolism (Willis, 
Carson et al. 1978; Balzarini, Karlsson et al. 1993). First ribavirin gets phosphorylated by 
adenosine kinase to ribavirin mono-phosphate (RMP), which is successively 
phosphorylated to ribavirin-di (RDP) and ribavirin-tri phosphate (RTP) by nucleoside 
mono- and di-phosphate kinases respectively (Gallois-Montbrun, Chen et al. 2003). 
Mammalian adenosine kinase does not metabolize ribavirin as efficiently as adenosine. 
Since, RTP is the major metabolite inside the cell, it is evident that the adenosine kinase 
is the rate-limiting step for its synthesis (Zimmerman and Deeprose 1978; Smee and 
Matthews 1986; Balzarini, Karlsson et al. 1993). Pharmacologically relevant 
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concentration of RTP (10-100 µM) can be achieved in a couple of hours of ribavirin 
treatment in mammalian cells, which is equivalent to that of intracellular concentration of 
ATP and GTP in cells without any treatment (Zimmerman and Deeprose 1978; Jones 
1980; Smee and Matthews 1986; Rankin, Eppes et al. 1989/1).  Levels of RTP drop 
significantly if ribavirin is removed from the treated cells in cell culture except 
erythrocytes. (Smee and Matthews 1986; Page and Connor 1990). This rapid degradation 
of RTP can contribute towards the lack of persistent antiviral activity of ribavirin in cell 
culture (Kirsi, North et al. 1983).  There have not been many studies done to evaluate the 
effect of virus infection on ribavirin metabolism. Infection of RSV had almost no effect 
on ribavirin metabolism (Smee and Matthews 1986). Deoxynucleotide of ribavirin have 
never been reported which suggests that RDP is not a substrate for ribonucleotide 
reductase. However, it is important to note that intracellular levels of deoxynucleotides 
are much lower than that of ribonucleotides, making their detection extremely difficult. 
None of the previous studies have found ribavirin incorporated in RNA of any ribavirin 
treated mammalian cell types (Zimmerman and Deeprose 1978). Also, ribavirin does not 
inhibit RNA polymerase I, RNA polymerase II activity (Eriksson, Helgstrand et al. 1977; 
Muller, Maidhof et al. 1977).  These results indicated that mammalian RNA polymerases 
cannot use RTP as a substrate. 
Mechanisms of action of ribavirin. 
The better understanding of ribavirin treatment failures is complicated by an 
unclear mechanism of action of ribavirin, partly due to its pleiotropic nature (Martin and 
Jensen 2008; Shah, Sunderland et al. 2010). There are six distinct proposed mechanism of 
action of the antiviral activity of ribavirin.  They can be subdivided into direct (if impacts 
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viral life cycle) or indirect mechanisms (Thomas, Feld et al. 2010). The direct 
mechanisms include (i) inhibition of viral RNA polymerase by phosphorylated ribavirin 
through physical interaction (Maag, Castro et al. 2001; Bougie and Bisaillon 2004/5/21).  
(ii) ribavirin acts as a mutagen by direct incorporation into viral genome, which results in 
inducing error catastrophe (Crotty, Cameron et al. 2001; Crotty, Cameron et al. 2002) 
(iii) ribavirin is also the substrate for viral guanylyl transferases, which leads to the 
inhibition of mRNA capping. The indirect mechanisms of ribavirin’s action include (i) 
inhibition of the host enzyme inosine monophosphate dehydrogenase (IMPDH), which is 
an essential enzyme for the de novo synthesis of GTP. This results in the strong depletion 
of cellular GTP pools required by virus for efficient replication (Malinoski and Stollar 
1980; Zhou, Liu et al. 2003). (ii) ribavirin has also been shown to modulate antiviral 
cellular responses such as the ability to induce a Th2 to Th1 shift in immune response to 
favor viral clearance (Tam, Pai et al. 1999). (iii) Recently, ribavirin has been shown to 
modulate the expression of interferon stimulated genes (ISGs) in cell culture system of 
RSV and in patients receiving ribavirin monotherapy before the start of standard 
treatment (Feld, Nanda et al. 2007). All the mechanisms of the antiviral activity of 
ribavirin are explained in detail below.  
One of the first indirect mechanisms of action of ribavirin was through the 
inhibition of host enzyme IMPDH. Many studies have demonstrated that ribavirin 
treatment results in the inhibition of host enzyme IMPDH, which is required by cells for 
purine biosynthesis (Muller, Maidhof et al. 1977; Zimmerman and Deeprose 1978). The 
mechanism of IMPDH inhibition is also investigated. The phosphorylated form of 
ribavirin metabolite RMP is a competitive inhibitor of IMPDH. In cells IMPDH is 
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responsible for converting its natural substrate IMP into xanthosine mono phosphate in 
the de novo synthesis of GMP (Fig. 1). However, in the presence of RMP this enzyme 
activity is reduced which results into reduced levels of GTP pools (Streeter, Witkowski et 
al. 1973; Balzarini, Karlsson et al. 1993).  This depletion in intracellular GTP pools 
reduces the supply of nucleotides for progeny viral RNA synthesis (Fig. 1). These results 
at least partially explained broad spectrum antiviral activity of ribavirin against many 
RNA and DNA viruses. Moreover, these results may also explain the toxicity of ribavirin 
observed in many human cells since ribavirin treatment modulates cellular nucleotide 
pools (Tam, Ramasamy et al. 2000). It became evident that ribavirin inhibits cellular 
IMPDH, however how much role this inhibition plays in the antiviral activity was not 
clear. This mechanism was supported by few independent studies with a drug-resistant 
strain of Sindbis virus, which replicated efficiently in cells with low intracellular GTP 
concentrations. This ribavirin resistant strain contained mutations in its viral guanylyl 
transferase gene, which increased its affinity for this enzyme (Malinoski and Stollar 
1980; Scheidel and Stollar 1991; Leyssen, Balzarini et al. 2005). 
 With several viruses it has been demonstrated that antiviral activity of ribavirin 
can be at least partially reversed if cells are treated with guanosine (Streeter, Witkowski 
et al. 1973; Wray, Gilbert et al. 1985; Smee, Bray et al. 2001; Zhou, Liu et al. 2003). 
Guanosine treatment replenishes the GTP pool independent of IMPDH. Guanine 
nucleotide is synthesized by purine nucleoside phopshorylase, which gets converted to 
guanosine monophosphate by hypoxanthine transferase and does not require IMPDH. 
The reversal in the antiviral effect of ribavirin by guanosine treatment does not 
necessarily show that inhibition of IMPDH is responsible for the antiviral activity of 
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ribavirin. Guanosine treatment results in elevated levels of GTP to compete with RTP and 
prevent its antiviral actions on viral RNA polymerases (Parker 2005). To exclude the 
possibility of RNA polymerase as a target of ribavirin, activity of a known inhibitor of 
IMPDH against many viruses was evaluated. The orthopox viruses, Sindbis virus, dengue 
virus etc. are sensitive to the treatment of mycophenolic acid (MPA) (Malinoski and 
Stollar 1980; Smee, Bray et al. 2001; Marroqui, Estepa et al. 2008). MPA is a non-
nucleoside inhibitor of IMPDH currently used in clinical settings as an 
immunosuppressive agent mainly for renal transplant (Kaplan 2006).  Because the only 
mechanism of action known of MPA is through the inhibition of IMPDH, these results 
suggests that reduction in the GTP pool might be sufficient to achieve the antiviral effect 
against these viruses. However, MPA treatment did not show any activity against HCV 
(Lanford, Chavez et al. 2001; Zhou, Liu et al. 2003) indicating that suppression of GTP 
pools is not always sufficient to obtain antiviral activity at least against HCV. Also, 
several studies with RSV and vaccinia virus showed no reversal of antiviral activity of 
ribavirin when co-treated with guanosine (Robins, Revankar et al. 1985; Smee and 
Matthews 1986). Imbalance caused in nucleotide pool by the inhibition of IMPDH by 
ribavirin treatment could result in substitution of nucleotides by viral polymerases. This 
subsequently results in increased number of viral genome mutations, which have been 
reported in many cases. 
 Despite ribavirin have been shown to reduce cellular GTP pools, results from 
various studies suggest the involvement of other mechanisms of action of ribavirin.  
Ribavirin treatment results in higher accumulation of intracellular RTP. Intracellular 
concentrations of ATP and GTP are ~3 and 0.5 mM (Jones 1980). Intracellular 
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concentration of RTP >0.1 mM is high enough to compete with natural nucleotides. As 
mentioned earlier, the triazole ring structure of ribavirin does not closely resemble any 
purine and could interact with viral RNA polymerases as a GTP or ATP analog. This 
interaction is even more probable when GTP levels are significantly dropped.  Under any 
circumstances if ribavirin is metabolized inside the cell it could modulate the activity of 
RNA polymerase in following ways: (1) RTP can physically inhibit viral polymerase by 
competing with natural nucleotides (2) RTP can cause chain termination by acting as 
alternative substrate (3) RTP can act as an alternative substrate and get incorporated into 
the viral genome, resulting into the formation of false copies. In both the first and second 
cases, RTP will immediately result in the inhibition of virus replication. However, in the 
third scenario viral genomes with many mistakes will be created and this will induce 
error catastrophe. Many in vitro studies have previously shown that RTP can inhibit viral 
RNA polymerases of various RNA viruses. Inhibition of influenza viral polymerase by 
RTP was competitive with the intracellular concentrations of ATP and GTP. (Eriksson, 
Helgstrand et al. 1977; Wray, Gilbert et al. 1985). Moreover, inhibition of viral RNA 
elongation required much higher concentration of RTP than incorporating RTP in viral 
RNA (Wray, Gilbert et al. 1985). This results suggest that RTP can inhibit viral RNA 
polymerase and cause chain termination but at much higher concentration (Fig 1). Studies 
with RNA polymerase of Reo virus and VSV have demonstrated that viral RNA 
polymerase can be inhibited by ribavirin nucleotides at lower concentrations than natural 
nucleotides (Toltzis, O'Connell et al. 1988/4; Rankin, Eppes et al. 1989/1). However, 
these studies did not evaluate the incorporation of ribavirin into viral genomic RNA and 
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inhibition of RNA synthesis does not imply that it occurred through competitive 
inhibition.   
 Recent publications have studied the interaction of RTP with RNA polymerases 
of polio virus, Hantan virus (HTNV) and HCV (Crotty, Maag et al. 2000; Maag, Castro 
et al. 2001; Bougie and Bisaillon 2003; Sun, Chung et al. 2007).  RNA polymerase of 
polio virus successfully incorporated RTP into viral RNA and continued the elongation 
without terminating the chain. Also, RNA polymerase of polio virus recognized RMP in 
the template as AMP or GMP and subsequently added UMP or CMP into the progeny 
strand (Crotty, Maag et al. 2000; Crotty, Cameron et al. 2001). Studies with Hantaan 
virus also showed that RTP synthesis directly corresponds to the antiviral activity of 
ribavirin and it also increases the mutation frequency in viral genome (Severson, 
Schmaljohn et al. 2003; Sun, Chung et al. 2007). For HCV RNA polymerase RTP is a 
poor substrate when compared to natural nucleotides.  Similar to polio viral RNA 
polymerase, HCV RNA polymerase also elongated the growing RNA strand after the 
incorporation of RMP and incorporated CMP or UMP in daughter strands (Maag, Castro 
et al. 2001; Vo, Young et al. 2003). However, significantly higher inhibition of HCV 
RNA elongation was also observed (Vo, Young et al. 2003). Moreover, at lower GTP 
levels RNA chain elongation was stalled by the HCV RNA polymerase and this was 
reversed by increasing the concentration of GTP (Vo, Young et al. 2003). Overall, these 
studies revealed that metabolites of ribavirin can both inhibit viral RNA synthesis and 
induce error catastrophe. Also, mechanisms of RTP activity can differ among different 
viral polymerases. 
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 Another direct mechanism of action of ribavirin has been shown to negatively 
influence viral mRNA capping enzyme (Cameron and Castro 2001) (Fig. 1.). The 5’-
phosphate of most eukaryotic mRNAs and many viral mRNAs possess a 
m7
GpppN cap 
structure, which plays a central role in stability and protein synthesis of mRNAs 
(Furuichi, LaFiandra et al. 1977; Shatkin 1985/2; Bougie and Bisaillon 2004/5/21). This 
is a two step process, in the first step 5’-triphosphate of RNA is hydrolyzed by RNA 
triphosphatase to 5’-diphosphate end. In the second step RNA guanylyltransferase 
interacts with GTP to form intermediate GMP-enzyme complex. The GMP from this 
complex is then transferred to the 5’-diphosphate of RNA by the same enzyme to form 
GpppN (Shuman 1982). The guanosine is then methylated to form the 
m7
GpppN cap by 
RNA methyl transferase. In a study with Sindbis virus genome suggested that resistance 
to ribavirin treatment is due to mutation in the coding region of RNA guanylyltransferase 
enzyme (Scheidel, Durbin et al. 1989/12; Scheidel and Stollar 1991). Similarly, ribavirin 
has been shown to inhibit the RNA cap synthesis of vaccinia virus (Goswami, Borek et 
al. 1979). More recently, a study provided evidence that RTP can be used as a substrate 
for vaccinia virus RNA capping enzyme and RMP-enzyme intermediate can be formed 
(Bougie and Bisaillon 2004/5/21).  Further, in vitro viral mRNA transcript containing a 
5’RpppN cap (where R is ribavirin and N is nucleotide) instead of 5’GpppN was 
synthesized (Bougie and Bisaillon 2004/5/21) (Fig. 1).  
 Ribavirin has also been shown to promote T-cell mediated immunity against viral 




T cells can be categorized in 
two different phenotypes Th1 and Th2 (Mosmann and Sad 1996).  The Th1 (CD4
+
) cells  
produce cytokines such as tumor necrosis factor-alpha (TNFα), interleukin (IL)-2 and 
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interferon gamma (IFNγ) especially to provide helper T cell driven cytotoxic T-cell 
response to viral infections. On the other hand Th2 (CD8
+
) cells produce IL-4, IL-5 and 
IL-10 which increases the synthesis of antibodies. This has been implicated with 





 T cells (Mosmann and Sad 1996). Few studies have 
demonstrated that ribavirin treatment can shift the cytokine profile by shifting the balance 
from Th2 to Th1 in human T cells (Tam, Pai et al. 1999). Recently, more evidence has 
demonstrated that ribavirin treatment can modulate the expression of certain ISGs in a 
cell culture system of RSV and in patients undergoing treatment for the HCV  
 
Figure 1. Proposed mechanisms of action of the antiviral action of ribavirin. Adapted 
from Feld et al. 2005.  
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Infection (Zhang, Jamaluddin et al. 2003; Thomas, Feld et al. 2010). Upregulation of 
ISGs in most cells occurs through binding of type I IFN onto IFN receptor. This results in 
the activation of Janus kinase1 (Jak1) and signal transducer and activator of transcription 
(STAT) signaling and results in the phosphorylation of STAT1, STAT2 and IRF9. This 
complex is known as ISGF3, translocates to the nucleus and acts as a transcription factor 
by binding onto IFN-sensitive response element (ISRE) to induce synthesis of ISGs. 
Since ribavirin-IFN treatment is significantly more successful than ribavirin mono 
therapy, the effect of ribavirin treatment in induction of various ISGs was recently 
evaluated. In a recent study a group of patients was given ribavirin prior to the ribavirin-
IFN treatment and another group was given the normal ribavirin-IFN treatment. When 
the gene expression data was compared, the group that received ribavirin prior to the 
ribavirin-IFN showed more ISG induction. These results indicate that ribavirin treatment 
may augment the activity of IFN by interacting with an antiviral signaling pathway (Feld, 
Nanda et al. 2007; Thomas, Feld et al. 2010).  
Although these proposed mechanisms came from the research performed over the 
last four decades, the exact mechanism of action of ribavirin is still unclear mainly due to 
its apparent pleiotropic nature (Vignuzzi, Stone et al. 2005; Dixit and Perelson 2006). 
The problems associated with ribavirin treatment and the future of this drug is discussed 
next.  
Ribavirin resistance and future. 
 As mentioned earlier approximately 170 million people are infected with HCV 
worldwide. The majority acquire chronic infections and that can lead to HCC or liver 
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cirrhosis (Dixit and Perelson 2006). Because there is no vaccine currently available the 
ribavirin-IFN therapy is the only approved treatment at this time. The IFN-α 
monotherapy against HCV genotype 1infected patients had a limited success (~20%) in 
achieving sustained virological response (SVR). However, addition of ribavirin increased 
the SVR rate to ~50-60% (Feld and Hoofnagle 2005; Dixit and Perelson 2006; Shah, 
Sunderland et al. 2010).  
It is evident that ribavirin has a key role in achieving SVR in HCV infections, 
however very little is known about factors involved in the resistance to ribavirin 
treatment. This is of utmost importance since, ~45-50% patients infected with HCV 
genotype 1 do not respond to ribavirin-IFN combination therapy and understanding the 
role of these factors can improve the therapeutic outcome of the ribavirin-IFN treatment. 
Many previous studies have thus far largely focused on the role of viral factors for the 
resistance to ribavirin treatment. Unlike other viruses like HIV or influenza, drug 
resistant mutations in HCV genome is very rare (Hofmann, Sarrazin et al. 2003; Sarrazin, 
Mihm et al. 2005; Johnson, Brun-Vezinet et al. 2007; Wohnsland, Hofmann et al. 2007). 
Recent studies have suggested that ribavirin resistance can be more influenced by host 
factors than viral determinants (Ibarra and Pfeiffer 2009; Thomas, Feld et al. 2010). A 
previous research demonstrated that most of the ribavirin resistance observed in a HCV 
replicon system was mainly due to the changes in the cell line (Pfeiffer and Kirkegaard 
2005). Moreover, it was also confirmed that this observed resistance to ribavirin is 
attributed to lower uptake in that cell line (Pfeiffer and Kirkegaard 2005) (Ibarra and 
Pfeiffer 2009).  
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For ribavirin to function, it needs to be transported in the cell. This transportation 
is facilitated by host nucleoside transporters, which are divided into two categories: 
equilibrative nucleoside transporters (ENT) and concentrative nucleoside transporters 
(CNT) (Jarvis, Thorn et al. 1998). Nucleosides can be transported bidirectionally by 
ENTs, whereas CNTs transport the nucleoside against the concentration gradient. Both 
ENTs and CNTs are known to transport synthetic nucleosides into the cell, including 
ribavirin (Errasti-Murugarren, Pastor-Anglada et al. 2007; Zhang, Visser et al. 2007). A 
majority of proposed mechanisms explained earlier require the import of ribavirin into 
the cell. A recent publication provided the evidence that cells treated with ribavirin for 
several passages developed the resistance to ribavirin and supported robust replication of 
polio virus. This resistance is analogous to chemotherapy resistance observed in some 
cancers. The polio virus is a model RNA virus known for its sensitivity to ribavirin.  
ribavirin sensitive cells treated with the inhibitor of nucleoside transporter mimicked the 
ribavirin resistant phenotype (Ibarra and Pfeiffer 2009).  
These results are clinically relevant and may explain the observed resistance in 
HCV patients with long exposure to ribavirin. However, they cannot explain why some 
patients completely do not respond to the treatment. We hypothesized that some cells are 
naturally resistant to ribavirin treatment even without any prior exposure to the drug and 
specific host factors and not viral determinants are responsible for such resistance. Our 
results clearly demonstrated that three out of seven chosen cell types were naturally 
resistant to ribavirin treatment without prior exposure to the drug against two prototypic 
NNS RNA viruses VSV and SeV.  Both of these viruses were previously shown to be 
very sensitive to the ribavirin treatment (Sidwell, Khare et al. 1975; Larson, Stephen et al. 
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1976; Toltzis and Huang 1986/6; Toltzis, O'Connell et al. 1988/4; Cuevas, Sanjuan et al. 
2005). Results of this study explain some treatment failures associated with ribavirin 
treatments. With the increased number of reported cases of HCV infections and next 
generation HCV inhibitors in the pipeline, it is extremely important to improve the 
antiviral efficacy of ribavirin. Future studies in search of ribavirin-like compounds to be 
used in combination with IFN remains to be the optimistic future for the HCV infected 
patients. 
Overall, this study demonstrates the important of studying the host factors 
interacting with virus to reduce the cell based antiviral drug resistance and improve the 
antiviral therapy. On other hand it is also very important to study host factors which 
suppresses the viral infection and mechanism of resistance to virus infection. This is 
important because viruses are being used as therapeutic options for the treatment of 
cancer or as vaccine vectors or gene therapy vectors. The resistance of specific pancreatic 











   
 
2.2 Introduction 
Ribavirin (ribavirin, also known as virazole), 1-ß-D-ribofuranosyl-1,2,4-triazole-
3-carboxamide, is the first synthetic, broad-spectrum antiviral nucleoside analog 
(Sidwell, Huffman et al. 1972), which has been shown to exhibit antiviral activity against 
many RNA and DNA viruses both in vitro and in vivo (Parker 2005; Vignuzzi, Stone et 
al. 2005; Dixit and Perelson 2006; Martin and Jensen 2008). ribavirin was originally 
approved for the treatment of respiratory syncytial virus (RSV) infection in children, and 
today is also used to treat Lassa fever and, most importantly, hepatitis C virus (HCV) 
infections of humans (Dixit and Perelson 2006). While ribavirin alone has little or no 
effect on viral replication in HCV patients (Wohnsland, Hofmann et al. 2007), it 
dramatically improves long-term antiviral response in many treated patients when used in 
combination with interferon (IFN) (Dixit and Perelson 2006; Martin and Jensen 2008). 
The mechanism of synergy between ribavirin and IFN (Buckwold, Wei et al. 2003; 
Zhang, Jamaluddin et al. 2003), which is critical for successful anti-HCV therapy, 
remains unclear (Dixit and Perelson 2006). 
Despite these successes with ribavirin/IFN combination therapy a large portion of 
patients are ‘‘non-responders’’ to this treatment (detectable HCV RNA throughout the 
treatment period). The mechanism of non-response to ribavirin/IFN treatment is highly 
controversial and, unfortunately, no alternative therapies exist for non-responders so far. 
The understanding of ribavirin treatment failures is complicated by an unclear 
mechanism of ribavirin action, partly due to its apparent pleiotropic nature (Dixit and 
Perelson 2006; Martin and Jensen 2008). Upon uptake, ribavirin is metabolized in vivo 
through 5′-phosphorylation by cellular kinases into ribavirin mono- (RMP), di- (RDP) 
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and triphosphate (RTP) (Willis, Carson et al. 1978; Balzarini, Karlsson et al. 1993; Wu, 
Larson et al. 2005). Six distinct mechanisms (which may work together) have been 
proposed for antiviral action of ribavirin against different viruses:  (Parker 2005; 
Vignuzzi, Stone et al. 2005; Dixit and Perelson 2006; Martin and Jensen 2008)  (i) 
inhibition of the host enzyme inosine monophosphate dehydrogenase (IMPDH) essential 
for the de novo synthesis of GTP; (ii) direct interaction of phosphorylated ribavirin with 
and inhibition of viral RNA polymerase, (iii) RNA chain termination as a result of 
incorporation of RTP (GTP analog) into replicating RNA strands by viral RNA 
polymerases; (iv) “error catastrophe” as a result of RTP incorporation into the viral 
genome paired with cytidine and uridine as a substitute for guanine and/or adenine, 
resulting in so called “lethal mutagenesis”, a meltdown of genetic information; v) 
inhibition of mRNA capping; and (vi) immunomodulation of antiviral cellular responses 
such as the ability to induce a Th2 to Th1 shift in the immune response. Previous studies 
in search of explanations for ribavirin treatment failures were largely focused on the role 
of viral determinants of ribavirin resistance (Vignuzzi, Stone et al. 2005; Wohnsland, 
Hofmann et al. 2007), as any antiviral mechanism of ribavirin via direct interactions with 
the viral RNA polymerase can hypothetically be overcome by mutations in the viral RNA 
polymerase. Such an escape via a single mutation in the RNA-dependent RNA 
polymerase has been shown to confer resistance to ribavirin via increased polymerase 
fidelity in poliovirus (Pfeiffer and Kirkegaard 2003; Vignuzzi, Stone et al. 2005) and 
foot- and mouth disease virus (Airaksinen, Pariente et al. 2003; Sierra, Airaksinen et al. 
2007).  
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While drug resistant viral mutants may explain at least some failures with 
ribavirin treatments, recent reports propose that cell-based resistance to ribavirin could be 
an important factor explaining the low antiviral activity of ribavirin in at least some 
experimental and clinical systems (Wohnsland, Hofmann et al. 2007). For example, 
Pfeiffer and Kirkegaard provided in vitro evidence that resistance of infected cells to 
ribavirin can be conferred not only via mutations in the viral genome (‘‘virus-based 
resistance’’) but also through changes in the ribavirin treated cells (‘‘cell-based 
resistance’’) (Pfeiffer and Kirkegaard 2003; Pfeiffer and Kirkegaard 2005). A recent 
study by Ibarra and Pfeiffer (Ibarra and Pfeiffer 2009) shows that the development of 
cell-based resistance to ribavirin treatment via decreased ribavirin uptake can greatly 
limit ribavirin antiviral activity. To examine whether certain cell types are naturally 
resistant to ribavirin even without prior drug exposure, we selected seven different cell 
lines from various hosts and compared them for the antiviral activities of ribavirin against 
two nonsegmented negative-strand RNA viruses (order Mononegavirales), vesicular 
stomatitis virus (VSV, family Rhabdoviridae) and Sendai virus (SeV, family 
Paramyxoviridae), which were previously shown to be highly sensitive to ribavirin 
treatment(Sidwell, Khare et al. 1975; Larson, Stephen et al. 1976; Toltzis and Huang 
1986/6; Toltzis, O'Connell et al. 1988/4; Cuevas, Sanjuan et al. 2005). Our results show 
dramatic cell-type dependent differences in the antiviral activities of ribavirin, ranging 
from virtually no effect to very effective inhibition of viral replication, indicating that 
some cell types are naturally resistant to ribavirin treatment even without prior exposure 
to this drug. The data presented in this study shed light on the mechanisms of the 
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ribavirin activity against VSV and SeV, and may explain at least some of the reported 
failures with ribavirin treatments. 
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2.3 Materials and methods 
Cell lines and viruses. 
The following seven cell lines were used in this study: Syrian golden hamster 
kidney fibroblast cells (BHK21, ATCC# CCL-10); human cervical adenocarcinoma cells 
(HeLA, ATCC# CCL-2); human epithelial lung carcinoma cells (A549, ATCC# CCL-
185), mouse mammary gland adenocarcinoma cells (4T1, ATCC# CRL-2539), human 
epidermal carcinoma cells (HEp2, ATCC# CCL-23); and African green monkey kidney 
cells (Vero, ATCC# CCL-81). In addition, we used BSRT7 cells which are derived from 
BHK21, constitutively express bacteriophage T7 polymerase and described by Buchholz 
et al.(Buchholz, Finke et al. 1999). Monolayer cultures of these cell lines were 
maintained in Minimum Essential Medium (Eagle’s MEM, Cellgro) or Dulbecco’s 
modified Eagle’s medium (DMEM, Cellgro) supplemented with 9% fetal bovine serum 
(FBS, Gibco) in a 5% CO2 atmosphere at 37°C. VSV-GFP is a recombinant wild type 
(wt) VSV (Indiana serotype) encoding GFP as an extra gene between the G and L genes 
(Das SC, Nayak D et al. 2006), kindly provided by Dr. Asit K. Pattnaik (University of 
Nebraska). Recombinant SeV-GFP (Fushimi strain) encoding GFP upstream of the NP 
gene (Wiegand, Bossow et al. 2007) was kindly provided by Dr. Wolfgang J. Neubert 
(Max-Planck-Institute of Biochemistry, Germany). To grow VSV-GFP or SeV-GFP, 
BHK21 or Vero cells, respectively, were infected with viruses at a multiplicity of 
infection (MOI) of 0.05 CIU (cell infectious units) per cell in MegaVir HyQSFM4 
serum-free medium (SFM, Hyclone) and incubated for 24–48 h at 34°C. This 
temperature (34°C) was chosen as it supported optimal replication of both viruses in the 
seven cell lines and all virus infections presented in this study were conducted at 34°C. 
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SeV-GFP was grown without acetylated trypsin in the medium as it has the wt monobasic 
trypsin-dependent cleavage site in the F protein mutated to an oligobasic cleavage site, 
allowing F activation in any cell type through an ubiquitous furin-like protease (Wiegand, 
Bossow et al. 2007). 
Inhibitors. 
Ribavirin was purchased from MP Biomedicals (cat. no. 196066); guanosine (cat. 
no. 101907), actinomycin D (ActD) (cat. no. 10465805) from MP Biomedicals and S-(4-
Nitrobenzyl)-6-thioinosine (NBMPR, also known as NBTI, cat. no. N2255) from Sigma-
Aldrich. Stock solution of ribavirin (0.1 M) was made in H2O, while ActD (2 mg/ml) 
was dissolved in 100% ethyl alcohol and guanosine (20 mM) and NBMPR (16.8 mM) in 
DMSO. 
Virus infections in the presence of inhibitors. 
Most experiments were conducted using 24-well tissue culture plates and nearly 
100% confluent cells treated with drugs in SFM (or mock-treated with SFM) and infected 
with VSV-GFP or SeV-GFP(or mock-infected with SFM) at MOI of 3 CIU/cell. The 
MOI for each virus/cell type combination was calculated by infecting each cell line with 
VSV-GFP or SeV-GFP serial dilutions in SFM and counting infectious foci with the aid 
of fluorescence microscopy. Ribavirin was added to the cells at 24 h before infection. 
After absorption of virus for 1 h in the absence of drugs (to rule out an interference of 
drugs with virus attachment/entry), SFM containing unabsorbed virus was removed, cells 
were washed three times with phosphate-buffered saline (PBS), and 300 ml/well of SFM 
with the same concentrations of drugs as in the pretreatment was added to each well. The 
fluorescence and bright field photographs of cells at 10x magnification were captured 24 
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h post infection (p.i.) or 48 h p.i. using an Olympus DP70 digital camera mounted on an 
Olympus IX71 inverted fluorescent microscope and Olympus DP Controller software. To 
examine effect of ribavirin on virus production, SFM containing infectious particles was 
collected 24 or 48 h p.i., and viral titrations were performed in 96- well plate format by 
infecting BHK21 (for VSV) or Vero cells (for SeV) with serial virus dilutions. For SeV 
titration, cells were overlaid with 100 ml SFM containing 1.2% Avicel RC-581 (FMC 
BioPolymer, Philadelphia, PA) as previously described (Matrosovich, Matrosovich et al. 
2006), while a 0.56 SFM/1% bactoagar mixture was used to overlay VSV infected cells. 
The effect of the exogenously added guanosine on VSV and SeV replication in the 
presence or absence of ribavirin was examined using confluent monolayers of cells in 96-
well tissue culture plates (performed three times, done in triplicates). Cells were infected 
with either VSV-GFP or SeV-GFP (or mock-infected with SFM) at MOI of 3 CIU/cell. 
After 1 h p.i., virus was removed and cells were washed with PBS and mock-treated or 
treated with the SFM containing 500 µM ribavirin or 50 µM guanosine, or ribavirin 
together with guanosine. Guanosine was dissolved in DMSO and the final concentration 
of DMSO in the media added to all wells was 0.25%. The intensity of fluorescent signal 
at 18 h p.i for VSV and 24 h p.i for SeV was quantified using a Fluorescence Multi-Well 
Plate Reader CytoFluor 4000 (PerSeptive Biosystems, Inc., Framingham, MA) with the 
standard in built CytoFluor filter set (excitation wavelength at 485 and emission 
wavelength at 530 nm). Values were corrected for background fluorescence by 




   
Plaque reduction assay to determine ribavirin inhibitory concentrations. 
To estimate the 50% and 90% inhibitory concentrations (IC50 and IC90) for 
ribavirin, antiviral screening was conducted by means of a plaque reduction assay using 
24-well tissue culture plates. Cells were infected with VSV-GFP or SeV-GFP in SFM (or 
mock-infected with SFM) at an MOI producing about 100 virus plaques per well on each 
cell line in the absence of ribavirin. After absorption of virus for 1 h without ribavirin (to 
rule out an interference with virus attachment/entry), SFM containing unabsorbed virus 
was removed, cells were washed three times with phosphate-buffered saline (PBS), and 
overlaid with 200 ml/well of SFM containing 1.2% Avicel RC-581 and increasing 
concentrations of ribavirin. Cells were then incubated for 24 h (VSV) or 48 h (SeV). 
Plaques were counted with the aid of fluorescence and bright field microscopy, and the 
50% (IC50) and 90% (IC90) inhibitory concentrations were calculated. Initial experiments 
were done using 0, 200, 500 or 1000 µM of ribavirin as it was done for virus infections at 
MOI 3 to determine the range of ribavirin activity for each virus/cell line combination. 
After that, all plaque reduction experiments were conducted using different ranges of 
ribavirin concentrations to more precisely determine the IC50 and IC90 values. Each of 
these experiments was performed at least twice (done in duplicates) and plaque numbers 
represent the mean 6 standard deviation of the mean. 
Virus growth analysis. 
The relative efficiency of the initiation of infection by VSV-GFP and SeV-GFP 
was measured by titrating viruses on the seven cell lines to determine the number of viral 
particles successfully initiating infection in a given cell line. For one-step growth kinetics 
analysis, confluent cell monolayers in 24-well plates were infected in parallel at an MOI 
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of 3 CIU/cell. At 1 h p.i., infection medium was aspirated, cells were washed three times 
with PBS (to minimize carryover of virions), and 300 ml of fresh SFM was added to each 
well. SFM from each well was collected at the specified time intervals, flash frozen at 
280uC, and analyzed by titration as described above. 
Ribavirin uptake assay. 
Cell monolayers were prepared exactly as for virus infections using 12- or 24-well 
tissue culture plates. The 
[3H]
ribavirin uptake experiments were conducted essentially as 
in (Ibarra and Pfeiffer 2009) but with some modifications. Cells were plated the day prior 
to generate about 90% confluence on the day of the experiment. For ribavirin uptake in 
the presence or absence of NBMPR (15 or 100 µM), cells (in triplicates) on 24-well 
plates were pretreated with this nucleoside transporter inhibitor in DMSO (or with 
DMSO alone) for 15 minutes. Cells were then washed with PBS and treated with 100 ml 
of SFM (same medium used for infections but without virus) containing 50 µM ribavirin 
1% of which was 
[3H]
ribavirin (ViTRax, Placentia, CA, cat. no. VT193, specific activity 5 
Ci/mmol) for 15 minutes in a 5% CO2 atmosphere at 37°C. For the long-term 
accumulation of ribavirin, cells (in triplicates) on 12-well plates were washed with PBS 
and treated with 275 ml of SFM (same medium used for infections but without virus) 
containing the same concentration of ribavirin/
[3H]
ribavirin (in the absence of NBMPR) as 
above but incubated for 1 h, 16 h or 24 h. To measure intracellular 
[3H]
ribavirin, cells 
were then placed on ice for 5 minutes (to stop an uptake) and washed 3 times with cold 
PBS. The cells were then trypsinized, pelleted at 200 x g for 4 minutes and cell pellets 
were frozen at -80°C. Nucleotide pool isolation was conducted as described in [26]. 
Specifically, tubes with frozen cell pellets were placed on ice and 75 ml of 1.3N cold 
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formic acid was added to each pellet, cell pellets were resuspended in formic acid and 
incubated for 1 h (tubes were vortexed every 15 minutes) on ice. After 1 h extraction 
period, the formic acid suspension was centrifuged at 17,000 x g, and the supernatant 
extracts (75 ml) were transferred to new tubes and quantified (15 ml) by scintillation 
counting for the intracellular [
3
H] accumulation. Cell numbers (from separate plates) 
were counted by two separate methods. First, cells were trypsinized and cell number was 
determined using a hemocytometer. Cell numbers were independently confirmed by 
staining monolayers (from a separate plate) with blue-fluorescent Hoechst 33342 dye 
(Invitrogen), which selectively stains nuclei. At least 5 random fields were photographed 
using a fluorescence microscope and DAPI filter and nuclei were then counted. Uptake 
values were determined by dividing the counts per minute (CPM) by number of cells 
(CPM/cell) in a 24-well plate. For ribavirin uptake in the presence of ActD, cells were 
pretreated with 5 mg/ml ActD for 2 h, media was aspirated (without cell washing), and 
then ribavirin uptake assay was conducted as described above.  
Cell viability assays. 
Cellular toxicity of ribavirin was determined using about 80% confluent cells 
treated with increasing ribavirin concentrations (0, 200, 500 or 1000 µM) at 37°C and 5% 
CO2 for 24 h. After 24 h, all cells reached 100% confluence and were analyzed by the 
following three assays: i) MTT (Biotium, cat. no. 30006, 96-well plate format) cell 
viability assay; ii) CellTiter-Glo luminescent cell viability assay (Promega cat. no. 
G7570, 96-well plate format); and iii) cell counting using trypan blue dye exclusion as an 
indicator of live cells (24-well plate format). MTT assay was conducted according to the 
manufacturer’s (Biotium) protocol. Briefly, after 24 h incubation with ribavirin, 10 ml of 
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MTT solution was added to each well and cells were incubated for 4 h at 37°C. Media 
was then removed and 200 ml of DMSO added to each well. OD values were measured 
using a Multiskan Ascent Microplate Photometer (Thermo Fisher Scientific) at a test 
wavelength of 570 nm and reference wavelength of 630 nm to determine the OD570–
OD630 signal. CellTiter-Glo assay was conducted according to the manufacturer’s 
(Promega) protocol and using 96-well white opaque culture plates (PerkinElmer, cat. no. 
6005680). After 24 h incubation with ribavirin, 100 ml of CellTiter-Glo reagent was 
added to each well. Plates were mixed for 2 minutes on orbital shaker to induce cell lysis, 
and incubated for 10 minutes to stabilize the luminescence signal. Luminescence was 
measured using Perkin Elmer TopCount NXT microplate luminescence counter. For 
trypan blue dye exclusion, 24-well plates were used. After 24 h incubation with ribavirin, 
cells were trypsinized and the number of viable cells was determined microscopically in a 












   
2.4 Results 
Identification of ribavirin-resistant cell lines. 
To determine whether ‘‘natural’’ (without pre-exposure to drug) resistance to 
ribavirin exists in some cell types, we selected seven commonly used cell lines (BHK21, 
BSRT7, HeLa, A549, 4T1, HEp2, and Vero) originated from various hosts and tissues, 
and compared them for the antiviral activity of ribavirin against VSV and SeV. To 
facilitate virus detection, we employed recombinant viruses containing an additionally 
inserted GFP gene (Fig. 2A). While such insertion results in a mild attenuation of VSV 
(Das, Nayak et al. 2006) and SeV (Wiegand, Bossow et al. 2007; Murphy AM and VZ 
2009) both viruses replicate similarly to parental wt strains and, thus, serve as useful 
models for studying replication of wt viruses. Cells were treated with increasing 
concentrations of ribavirin added to the media 24 h before infection, and then infected 
with viruses at MOI of 3 CIU/cell with ribavirin treatment continued after virus 
absorption. The MOI for each cell line was calculated individually by titrating viruses on 
each of the seven cell lines as described in Materials and Methods and Table 2. Following 
ribavirin treatment and virus infection, pictures were taken 24 h post infection (p.i.) for 
VSV or 48 h p.i. for SeV using fluorescence and light microscopy. As shown in Figure 
2B, GFP associated fluorescence attributable to viral replication was readily detectable in 
all tested cells lines infected with VSV or SeV when no ribavirin was added to the media, 
indicating that all cell lines were susceptible to infection by these two viruses. Consistent 
with previous studies demonstrating antiviral activity of ribavirin against VSV, ribavirin 
effectively inhibited VSV in BSRT7, HeLa and HEp2 cells even at the lowest (200 µM) 
tested drug concentration (Fig. 2B). However, ribavirin had a surprisingly mild effect on 
the VSV-driven GFP expression in BHK21, Vero and A549 cells even when used at 1000 
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µM concentration with a somewhat intermediate effect in 4T1 cells (Fig. 2B). In general, 
ribavirin inhibited SeV replication to a greater degree than VSV with markedly stronger 
inhibition in 4T1 cells. However, Figure 2B clearly shows a similar pattern of ribavirin 
resistance in BHK21, Vero and A549 cells for VSV and SeV, suggesting that cellular 
rather than virus-specific factors determine the dramatic  differences between tested cell 
lines in their response to ribavirin. A similar pattern was also observed when ribavirin 
was added to the medium 6 h (rather than 24 h) before or 1 h after infection (without 
ribavirin pretreatment), although in general ribavirin was more effective when longer 
pretreatments were conducted. In addition, a similar pattern of ribavirin effect in the 
seven cell lines was observed when experiments were conducted at 37°C rather than at 
34°C [34°C was chosen for experiments presented here as it supported optimal 
replication of both viruses in the seven cell lines or with cells of various passage level (3 
to 20 passages) or confluence (70%), demonstrating that the observed effect was not 
determined by the state of the cells. To determine whether GFP levels correlated with the 
production of new infectious virus particles, the medium was collected and subjected to 
plaque assay on BHK21 (for VSV) or Vero (for SeV) cells. Virus titration analysis 
showed a clear correlation between GFP signal and the number of infectious virus 
particles produced in different cell lines under various treatment conditions (Fig. 2C). 
Next, we examined a possibility that a higher sensitivity of VSV and SeV to ribavirin in 
4T1, BSRT7, HeLa and HEp2 was due to the increased cellular toxicity of ribavirin in 
these cell lines, which could result in the decreased ability of these cells to efficiently 
support viral replication. To address this issue, we used three different assays to measure 
cell viability using cells prepared and ribavirin treated the same way as for virus 
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infections shown in Figure 2: i) colorimetric MTT assay based on the reduction of the 
yellow tetrazolium salt MTT to the insoluble purple formazan crystals, which are 
solubilized by the addition of a detergent in metabolically active cells (Fig. 3A); ii) 
luminescent ‘‘CellTiter-Glo’’ assay based on quantitation of the intracellular ATP 
content as an indicator of metabolically active cells (Fig. 3B); iii) live cell counting using 
trypan blue dye exclusion as an indicator cell membrane integrity in the live cells (Fig. 
3C). Using these three different methods (as described in Materials and Methods), we 
showed that ribavirin treatment even at 1000 µM concentration did not produce any 
statistically significant decrease in cell viability in any of the tested cell lines under our 
experimental conditions (Fig. 3), indicating that the observed pattern of ribavirin antiviral 
activity was not due to the differential ribavirin cytotoxicity in the tested cell lines (Fig. 
3). To prepare cells for these assays, 80% confluent cells were treated with ribavirin for 
24 h (same conditions used for virus infections in Figure 2). After 24 h treatment, all 
tested cell lines reached 100% confluence suggesting that ribavirin did not produce any 
substantial cytotoxicity that would prevent cell growth. However, we recognize that the 
cell viability assays conducted on 100% confluent cells may not be sensitive enough to 
detect all adverse effects of ribavirin on the host cell. Nevertheless, the absence of 
significant drop in cell viability by 3 independent assays were in good agreement with the 
lack of visible differences between ribavirin treated and untreated cells using light 
microscopy (Figure 2B). All infection experiments described above were conducted at 
MOI of 3 CIU/cell to achieve one-step replication of viruses in all tested cell lines. We 
also conducted additional experiments with cells infected at MOI 0.2, 0.5, 1, 10 or 20 in 
the presence of increasing concentrations of ribavirin (same range as above) and observed 
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a similar pattern of ribavirin resistance in Vero, BHK21 and A549, indicating that this 
effect was MOI independent. To further confirm the MOI-independent character of 
ribavirin resistance in Vero, BHK21 and A549 cells, we conducted a plaque reduction 
assay in the presence of ribavirin, which also allowed us to calculate the 50% and 90% 
inhibitory concentrations (IC50 and IC90) of ribavirin for each virus/cell type combination, 
as described in Materials and Methods. As shown in Figure 4 and summarized in Table 3, 
the IC50 and IC90 values were in good agreement with our data using MOI 3 infections 
(Fig. 2). We find especially striking resistance of Vero cells to ribavirin with IC50=2250 
µM for VSV and 1550 µM for SeV and IC90>3000 µM for both viruses. Compared to 
SeV, VSV was consistently more resistant to ribavirin in all tested cell lines, which might 
be associated with its markedly faster growth in all tested cell lines (addressed below). 
Nevertheless, the similar cell type dependent pattern of ribavirin resistance for VSV and 
SeV suggests that cellular determinants play a major role in ribavirin resistance. 
Analysis of ribavirin uptake in different cell lines. 
A recent study by Ibarra and Pfeiffer (2009) showed that the development of cell-
based resistance to ribavirin treatment via decreased ribavirin uptake can greatly limit 
ribavirin antiviral activity. Therefore, we wanted to examine a possibility that the 
ribavirin resistance of Vero, BHK21 and A549 cells was a result of defective ribavirin 
uptake in these cell types, using methodology similar to that described previously (Ibarra 
and Pfeiffer 2009). To measure ribavirin short-term uptake, cells were treated with SFM 
(same media type used for infections but without virus) containing 50 µM ribavirin (1% 
of which was [
3
H] ribavirin). After 15-minute incubation, cells were collected and 
measured for the level of [
3
H]ribavirin uptake normalized to the number of cells as 
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described in Materials and Methods. As shown in Figure 5A (black bars), all tested cell 
lines showed somewhat similar levels of ribavirin import after 15-minute incubation, 
indicating that none of the tested cell lines was defective in ribavirin uptake. To confirm 
that the slightly lower [
3
H]ribavirin counts presented in Figure 5A for BHK21, A549, and 
Vero cells reflect active uptake of ribavirin into the cells (rather than background counts), 
we also analyzed ribavirin uptake in cells pretreated with increasing concentrations of 
nitrobenzylthioinosine (NBMPR), a specific inhibitor of equilibrative nucleoside 
transport via ENT1 (inhibited at lower NBMPR concentrations) and ENT2 (inhibited at 
higher NBMPR concentrations) nucleoside transporters, which were (especially ENT1) 
previously shown to be primarily responsible for ribavirin import into the cells [28,29]. 
Our results clearly showed ribavirin uptake was inhibited in most cell lines at both lower 
(15 µM) and higher (100 µM) NBMPR concentrations (Fig. 5A), confirming that ENT 
play at least some role in the influx of ribavirin into all tested cell types. Interestingly, we 
were unable to see any additional decrease of ribavirin uptake in 4T1 cells at the higher 
NBMPR concentration (100 µM) where both ENT1 and ENT2 are inhibited (Ibarra and 
Pfeiffer 2009). However, a decrease was observed at 15 µM NBMPR concentration, 
suggesting that ENT1 is involved in the ribavirin uptake in this cell line. While our short-
term uptake experiments did not reveal any defects in ribavirin import in the seven cell 
lines, we wanted to see whether long-term accumulation of [
3
H]ribavirin, which depends 
on the ribavirin metabolism) was different in the seven cell lines. To test it, we conducted 
a similar uptake experiment described above but with cells treated with [
3
H]ribavirin for 
1 h, 16 h and 24h (instead of 15 minutes). As shown in Figure 5B, dramatic variations 
were observed in the long-term accumulation of ribavirin in different cell types. 
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Importantly, it correlated with the antiviral efficacy of ribavirin in the tested cell lines. 
Thus, all 3 ribavirin-resistant cell lines, BHK21, A549 and especially Vero showed 
markedly decreased levels of ribavirin accumulation suggesting that such the differences 
in the intracellular ribavirin metabolism may be responsible for natural resistance of 
BHK21, A549 and Vero cells to antiviral ribavirin treatment (Ibarra and Pfeiffer 2009). 
Neutralizing effect of guanosine and actD on the antiviral activity of ribavirin 
One of the major proposed mechanisms of ribavirin antiviral action is the inhibition of 
the host enzyme IMPDH essential for the de novo synthesis of GTP. Moreover, a recent 
study suggests that inhibition of IMPDH and the consequent decrease in the cellular GTP 
pool (but not interactions of ribavirin metabolites with viral polymerase) is the 
predominant mechanism of action of ribavirin against RSV (a paramyxovirus) (Leyssen, 
Balzarini et al. 2005). To examine whether ribavirin inhibits VSV and SeV in all seven 
tested cell lines primarily via depletion of the GTP pool, we analyzed the effect of 
exogenously added guanosine on the antiviral effect of ribavirin. If GTP depletion alone 
is sufficient for inhibition of viral replication, we expected complete neutralization of the 
ribavirin effect in cells treated with a combination of ribavirin (500 µM) and guanosine 
(50 µM). The selected 50 µM guanosine concentration should result in dramatic increase 
in the intracellular GTP levels. According to previous studies, even 10µM exogenous 
guanosine produces at least 4-fold excess of physiological GTP levels within Vero, 
HepG2, MDCK and other cell lines (Wray, Gilbert et al. 1985; Leyssen, Balzarini et al. 
2005; Sun, Chung et al. 2007). Cells were infected with either VSV-GFP or SeV-GFP at 
MOI of 3 CIU/cell, and then mock treated or treated with the SFM containing ribavirin or 
guanosine, or ribavirin together with guanosine. The intensity of GFP-associated 
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fluorescence attributable to viral replication was quantified (as described in Materials and 
Methods) at 18 h p.i for VSV and 24 h p.i for SeV (Fig. 6). As expected, guanosine 
treatment alone had no significant effect on virus replication (Fig. 6) in most cell lines. It 
had also a clear neutralizing effect on ribavirin in BHK21 and A549 cells, already highly 
resistant to ribavirin (Fig. 6). Intriguingly, guanosine had an intermediate neutralizing 
effect in BSRT7 cells for VSV and a very small effect on ribavirin activity in the 
ribavirin sensitive HeLa, 4T1 and HEp-2 (and BSRT7 for SeV) cells (Fig. 6), although all 
tested cell lines had somewhat similar levels of [
3
H]-guanosine uptake. The addition of 
50 µM guanosine was unable to neutralize the ribavirin effect in these 4 cell lines even 
when the ribavirin concentration was lowered to 200 or 100 µM. Also, a similar result 
was obtained when 200µM guanosine was added to the medium. These data suggest that 
a decrease in the cellular GTP pool is not the predominant mechanism of ribavirin action 
against VSV and SeV in HeLa, 4T1, HEp-2 and BSRT7 cells, and that other mechanisms 
also contribute to ribavirin activity against these two viruses in those cell lines. 
 Previous studies showed that actinomycin D (ActD), an inhibitor of DNA-primed 
RNA synthesis (but not viral RNA-dependent RNA synthesis), was able to revert the 
antiviral effect of ribavirin against several RNA viruses, including VSV (Toltzis and 
Huang 1986/6), RSV(Smee and Matthews 1986), Sindbis virus (Malinoski and Stollar 
1980) and rotavirus (Smee, Sidwell et al. 1982). Two mechanisms of such reversion were 
proposed including the stabilization of cellular GTP levels (Malinoski and Stollar 1980; 
Smee, Sidwell et al. 1982; Smee and Matthews 1986; Toltzis and Huang 1986/6) and 
inhibition of ribavirin triphosphate (RTP) production (Smee and Matthews 1986). To 
examine whether ribavirin neutralization by ActD can be also reproduced in case of SeV 
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and whether it is cell type dependent, we infected cells with VSV-GFP or SeV-GFP at 
MOI 3 CIU/cell and treated these cells with ActD (5 mg/ml) or ribavirin (500 µM) alone 
or with both drugs together at 1 h p.i. Photographs of infected cells were taken at 24 h p.i. 
and the media from each well was collected and titered to determine the number of new 
infectious particles produced. As shown in Figure 7 (A–C), ActD had a clear neutralizing 
effect on ribavirin in most cell lines, while it had a somewhat mild effect on viral 
replication when used alone in most cell lines with the strongest negative effect observed 
in HEp2 cells for SeV and HeLa cells for VSV. The tolerance of both viruses to ActD 
treatment is consistent with a relative independence of their exclusively cytoplasmic 
replication cycle on new mRNA synthesis by cellular RNA polymerase II, a target of 
ActD. To rule out a possibility that ActD treatment affected ribavirin import into the 
cells, all seven cell lines were treated with ActD (or mock-treated) for 2 h followed by a 
[
3
H]ribavirin uptake experiment conducted as described in Materials and Methods. Our 
results showed that ActD treatment did not inhibit ribavirin uptake, but actually resulted 
in a slight increased uptake of ribavirin, demonstrating that the observed reversal of 
ribavirin antiviral action (Fig. 7) was not due to the interference of ActD with ribavirin 
uptake. 
Resistance of cell lines to ribavirin and their ability to support viral replication 
As noted, the seven cell lines used in this study were selected solely based on their ability 
to support replication of VSV and SeV. To assess any possible correlation between the 
general ability of these viruses to replicate in these cell lines and their resistance to 
ribavirin, we compared VSV and SeV for their ability to initiate infection and for their 
replication kinetics in these cell lines without ribavirin treatment. First, VSV-GFP or 
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SeV-GFP virus stocks were titrated in parallel on different cell lines and the relative 
ability of each virus to initiate virus infection was calculated by counting infectious foci 
generated on each cell line. As shown in Figure 8A (and Table 2 with the numbers 
calculated based on the Figure 8A data), Vero, BHK21 and A549 cells, all highly 
resistant to ribavirin, were among the four cell lines most susceptible to VSV infection. 
Consequently, for our MOI 3 infections described in Figures 2, 4, 6 and 7 to achieve 
VSV MOI 3 infection for each cell line, for each 3 ml of the VSV-GFP virus stock added 
to the ribavirin-resistant BHK21 cells (13.2 µl to A549, 23.7 µl to Vero), 227 µl of the 
same stock was added to the ribavirin-sensitive 4T1 and HEp2 and 132 µl to HeLa cells 
(Table 2). However, ribavirin-sensitive BSRT7 cell line was found to be as susceptible to 
VSV as the most ribavirin-resistant Vero cells (Figure 8A and Table 2). In case of SeV, 
most cell lines (except for 4T1) showed somewhat similar rates of viral infection 
initiation for SeV, without any strong correlation with ribavirin sensitivity (Figure 8A 
and Table 2). 
We also conducted one-step growth kinetics analysis by infecting each cell type 
with VSV-GFP or SeV-GFP at MOI of 3 CIU/cell (MOI was calculated individually for 
each virus/cell type combination) and measuring production of new infectious particles 
by collecting medium from each well at specified time points and titrating it as described 
in Materials and Methods. While some correlation can be seen in SeV with its fastest 
growth kinetics (and highest titers) in BHK21, A549 and Vero cells (all three resistant to 
ribavirin), it is less apparent in the case of VSV, which grows relatively similarly in most 
cell lines (Fig. 8B). Together, all these results show no clear correlation between abilities 
of cell lines to support viral replication and their resistance to ribavirin, although the 
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abilities of cells to support robust virus replication may be an important factor that would 
allow successful replication in the presence of ribavirin as all three ribavirin-resistant cell 
lines supported high replication levels of both VSV and SeV. Nevertheless, our results 
show that virus growth phenotype alone (e.g., VSV in BSRT7) cannot be used to predict 
















   
 
2.5 Discussion 
In this study, we compared the antiviral activity of ribavirin against two 
prototypic members of the order Mononegavirales, VSV (a rhabdovirus) and SeV (a 
paramyxovirus), in seven different cell lines originated from various hosts and tissues. 
Previous studies showed that ribavirin can effectively inhibit replication of VSV (Toltzis 
and Huang 1986/6; Toltzis, O'Connell et al. 1988/4; Cuevas, Sanjuan et al. 2005) and 
SeV (Sidwell, Khare et al. 1975; Larson, Stephen et al. 1976) as well as other members of 
Mononegavirales (Hruska, Bernstein et al. 1980; Smee and Matthews 1986; Toltzis and 
Huang 1986/6; Toltzis, O'Connell et al. 1988/4; Jordan, Briese et al. 1999/9; Crotty, 
Cameron et al. 2002; Cuevas, Sanjuan et al. 2005; Leyssen, Balzarini et al. 2005; Elia, 
Belloli et al. 2008; Pelaez, Lyon et al. 2009). However, in most of these studies only one 
or two different cell lines were tested. The seven cell lines used in this study were 
selected solely based on their ability to support replication of both viruses. The two-virus 
approach allowed us to discriminate between virus specific and cell-based resistance to 
ribavirin treatment because, although both viruses belong to the same order 
Mononegavirales, they belong to different families and have noticeably different growth 
kinetics in these cell lines.  
Our results show striking differences between cell lines, ranging from the 
extremely poor antiviral activity of ribavirin in Vero cells (e.g., IC50 = 2250 µM for VSV 
and 1550 µM for SeV; IC90 >3000 µM for both viruses), moderate activity in BHK21 and 
A549 cells, and very effective inhibition in HEp2, HeLa, 4T1 and BSRT7 cells (IC50=10 
µM, IC90=40 µM for VSV in BSRT7; IC50=16 µM, IC90=40 µM for SeV in BSRT7). 
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This pattern was confirmed using various infection and ribavirin treatment conditions, 
with cells infected and treated at 34 or 37°C, high or low MOI, and with ribavirin 
treatment starting at 24 h before infection, 6 h before infection, or 1 h p.i. Using three 
different cell viability assays, we showed that ribavirin treatment even at 1000 µM 
concentration did not produce any significant cytotoxicity in any of the tested cell lines at 
our experimental conditions, nor did we observe any significant differences between 
tested cell types, indicating that the observed pattern of ribavirin resistance was not due 
to differences in ribavirin toxicity. It is important to emphasize that the median ribavirin 
plasma concentration in HCV patients at the peak of ribavirin therapy is between 6.6and 
9 µM (Glue 1999; Aguilar Marucco, Gonzalez de Requena et al. 2008; Loustaud-Ratti, 
Alain et al. 2008; Maynard, Pradat et al. 2008). Therefore, the IC50 and IC90 values for 
Vero, BHK21 and A549 cells (Table 3) indicate extremely high resistance of these cell 
types to ribavirin. 
Our data strongly argue that the observed resistance of VSV and SeV to ribavirin 
in Vero, BHK21 and A549 was not due to the generation of ribavirin-resistant mutants in 
these cells. Such ‘‘virus-based’’ resistance mechanism was previously described for 
several other RNA virus groups, including polioviruses (Pfeiffer and Kirkegaard 2003; 
Vignuzzi, Stone et al. 2005), foot-and mouth disease virus (Airaksinen, Pariente et al. 
2003; Sierra, Airaksinen et al. 2007) and recently for HCV (Cuevas, Gonzalez-Candelas 
et al. 2009). However, even when our cells were treated with ribavirin starting as early as 
24 h before infection (Fig. 2), we observed little effect of ribavirin on viral replication in 
ribavirin-resistant cells, ruling out any possibility of virus adaptation to ribavirin. In 
addition, when VSV was passed 10 to 15 times in HeLa, BSRT7 and BHK21 cells in the 
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presence of sub-inhibitory ribavirin concentrations, no viral adaptation to ribavirin was 
ever observed (N.R.S. and V.Z.G., unpublished data). These observations are consistent 
with a previous study by Cuevas et al. demonstrating that even after 100 generations 
under sub-inhibitory concentrations of ribavirin, resistance of VSV to ribavirin was not 
achieved, with selected populations generally less fit than the ancestral population both in 
the presence and absence of ribavirin (Cuevas, Sanjuan et al. 2005). 
A recent study by Ibarra and Pfeiffer (Ibarra and Pfeiffer 2009) showed that the 
development of cell-based drug resistance after continuous ribavirin treatment via 
decreased drug uptake can greatly limit ribavirin efficacy. In addition, any potential 
antiviral mechanism absolutely relies on ribavirin entry into the cell. Therefore, we 
compared our seven cell lines for their ability to internalize ribavirin. Our results showed 
a similar ribavirin uptake in all tested cell lines after 15-minute treatment, indicating that 
none of the tested cell lines was defective in ribavirin uptake. In addition, using NBMPR, 
a specific inhibitor of equilibrative nucleoside transporters, we confirmed that ENT1 and 
possibly ENT2 transporters are involved in the ribavirin uptake (Jarvis, Thorn et al. 1998; 
Fukuchi, Furihata et al. 2010). A similar ribavirin uptake level by all tested cell lines is 
not surprising as ENTs are ubiquitously expressed in virtually all cell types (Endres, 
Moss et al. 2009). However, when we analyzed long-term ribavirin accumulation in cells 
after 16 h or 24 h treatment, a totally different picture was observed. Four cell lines 
sensitive to ribavirin (BSRT7, HeLa, HEp2 and 4T1) showed significantly higher levels 
of ribavirin accumulation compared to ribavirin-resistant BHK21, A549 and Vero. Vero 
cells had particularly low accumulation which may explain the highest resistance of this 
cell line to ribavirin treatment among all the cell lines tested in our study (Table 3). 
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It is important to note that while the 15-minute uptake say determines the ability 
of cells to internalize ribavirin, the long-term accumulation is dependent on the cellular 
metabolism of ribavirin. Neutral ribavirin molecule can be transported freely in and out 
of a cell via ENTs, but once it is phosphorylated, negative-charged RMP, RDP, or RTP 
are trapped inside the cells. A good illustration of the difference between the ribavirin 
uptake and its long term accumulation is ribavirin hyperaccumulation in erythrocytes 
resulting in hemolytic anemia in some ribavirin-treated patients. Similarly to nucleated 
cells, ribavirin is transported into erythrocytes via ENTs (Jarvis, Thorn et al. 1998) and 
converted into RMP, RDP and RTP. However, unlike nucleated cells, they lack the 
phosphatases needed to hydrolyze RMP/RDP/RTP into ribavirin [(Page and Connor 
1990; Gish 2006; Endres, Moss et al. 2009). Recent study by Endres et al. (2009) directly 
showed that total radioactivity of ribavirin after long-term administration is 
predominantly attributed to RMP and RTP (Endres, Moss et al. 2009). 
Hyperaccumulation of these molecules, along with other factors, results in cellular 
toxicity of erythrocytes and subsequent anemia (Gish 2006). 
While future studies are warranted to directly analyze ribavirin metabolism in the 
seven cell lines, our results indicate that these cell lines may significantly differ in their 
abilities to accumulate sufficient amounts of phosphorylated ribavirin metabolites 
required for effective ribavirin antiviral actions. RMP is believed to play the major 
antiviral role as a competitive inhibitor of the enzyme IMPDH essential for the de novo 
synthesis of GTP and is also capable of binding and inhibiting at least some viral 
polymerases (Parker 2005), including viral polymerase of VSV (Toltzis and Huang 
1986/6; Toltzis, O'Connell et al. 1988/4; Cuevas, Sanjuan et al. 2005). RTP may also play 
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an important role in the inhibition of VSV and SeV replication via interaction with viral 
polymerase (shown for RTP and VSV (Toltzis, O'Connell et al. 1988/4)), ‘‘error 
catastrophe’’ or any other mechanisms which involves RTP as a substrate for viral RNA 
polymerase. 
To examine whether ribavirin inhibits VSV and SeV primarily via depletion of 
the GTP pool, we treated VSV or SeV infected cells with ribavirin in the presence of 
extracellular guanosine which restores normal intracellular GTP level. Guanosine had a 
clear (almost 100%) neutralizing effect on ribavirin in BHK21, A549 and Vero cells, 
which are already highly resistant to ribavirin. However, very little effect was observed 
on the ribavirin activities in ribavirin-sensitive cells, especially HeLa, 4T1 and HEp-2 
cells. Together, these data suggest that a decrease in the cellular GTP pool is not the 
predominant mechanism of ribavirin action against VSV and SeV in HeLa, 4T1, HEp-2 
and BSRT7 cells, and that other mechanisms also contribute to ribavirin activity against 
these two viruses in these cell lines. 
Unlike guanosine, ActD was able to effectively neutralize ribavirin in all tested 
cell lines. Previous studies showed that ActD neutralizes ribavirin effects via two 
mechanisms (likely not mutually exclusive). Malinoski and Stollar (1980) showed that 
ActD neutralized effect of ribavirin against Sindbis virus by maintaining the GTP pool 
size at its normal level (the mechanism of this stabilization is still unknown) (Malinoski 
and Stollar 1980). A similar effect of ActD on GTP pool stabilization was shown by 
Smee and Matthews (1986) in RSV-infected cells treated with ribavirin. However, they 
also analyzed the metabolism of RMP to its mono-, di-, and triphosphate derivatives in 
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uninfected and RSV-infected cells, and concluded that ActD also neutralized ribavirin 
effect via inhibition of RTP production (Smee and Matthews 1986). 
Based on the ability of ActD (but not guanosine) to neutralize the effect of 
ribavirin in ribavirin-sensitive cell lines (HeLa, 4T1, HEp-2 and BSRT7), we hypothesize 
that ribavirin antiviral activity in these cell lines depends not only on the depletion of the 
GTP pool (can be restored by guanosine addition) but also on the successful 5’- 
phosphorylation of ribavirin into RMP/RDP/RTP (Willis, Carson et al. 1978; Balzarini, 
Karlsson et al. 1993; Wu, Larson et al. 2005) which were previously shown to inhibit 
VSV RNA synthesis in vitro (Toltzis, O'Connell et al. 1988/4). At the same time, we 
think that ribavirin acts in ribavirin-resistant cell types (BHK, A549 and Vero) primarily 
via depletion of GTP pool due to insufficient amounts of phosphorylated ribavirin 
molecules in these cells, explaining why the effect of ribavirin can be completely 
reversed in these cell lines by guanosine. Further experiments are planned to test this 
hypothesis and further investigate the mechanism of ribavirin neutralization by ActD.  
Overall, our data point out to an interesting possibility that the mechanism of 
virus inhibition by ribavirin may be more dependent on cell type than we currently 
expect. This could explain numerous conflicting reports regarding the ‘‘true’’ mechanism 
of ribavirin action proposed by different research groups for the same virus (Parker 2005; 
Vignuzzi, Stone et al. 2005; Dixit and Perelson 2006; Martin and Jensen 2008). 
Furthermore, we anticipate that different results for other viruses might be obtained in the 
cell lines utilized here. For example, a recent study demonstrated an effective inhibition 
of canine distemper virus (CDV, family Paramyxoviridae, genus Morbillivirus) in Vero 
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cells [IC50=20–50 µM, IC80=40–110 µM] (Elia, Belloli et al. 2008). This result suggests 
that CDV and SeV might be inhibited by ribavirin via different mechanisms. 
At present, we cannot explain dramatic differences between BHK21 and BSRT7 
cells in their resistance to ribavirin and the long term ribavirin accumulation. BSRT7 cell 
line is derived from BHK21 and constitutively express bacteriophage T7 polymerase 
under control of the cytomegalovirus promoter and the neomycin resistance gene 
(Buchholz, Finke et al. 1999). Although we cannot explain why these two cell lines are so 
different in regard to ribavirin, we also noticed significant differences in cell appearance, 
cell growth kinetics, viral growth kinetics and the phenotype of infectious foci for VSV 
and SeV between BHK and BSRT7 cells, suggesting that some additional changes were 
introduced into BSRT7 when or since this recombinant cell line was generated, or that T7 
polymerase expression may be responsible for some or all of those phenotypes.  
We believe the very similar pattern of ribavirin activity against VSV and SeV in 
seven different cells lines may indicate that these two viruses are inhibited by ribavirin 
via the same mechanism. Although the mechanism of SeV (genus Respirovirus) 
inhibition by ribavirin has not been previously studied, a previous study on RSV (another 
member of the family Paramyxoviridae, but belongs to the genus Pneumovirus) suggests 
the predominant mechanism of action of ribavirin against RSV is inhibition of cellular 
IMPDH activity by RMP (and consequent decrease in the cellular GTP pool) rather than 
interactions of ribavirin metabolites with the viral polymerase (Leyssen, Balzarini et al. 
2005). In contrast, a previous study using in vitro transcription reactions with purified 
VSV virions demonstrated that RMP, RDP and RTP significantly inhibited viral 
polymerase activity and hypothesized that these molecules reversibly inhibit an initiating 
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step of VSV RNA synthesis (Toltzis, O'Connell et al. 1988/4). Further experiments are 
needed to examine molecular mechanisms of VSV and SeV inhibition by ribavirin.  
Overall, our data demonstrate the antiviral activity of ribavirin is naturally limited 
in many cell types which may explain at least some ribavirin treatment failures. Further 
studies aimed at the understanding molecular determinants responsible for cell-based 
resistance to ribavirin are warranted. This understanding may become an important tool 
for tailoring individualized treatments with ribavirin (and possibly other nucleoside 
analogs) against important viral pathogens. Future experiments are also needed to 
determine whether the observed differences between different cell lines are limited only 
to non-segmented negative-strand RNA viruses by analyzing effect of ribavirin on 
replication of positive-strand RNA or segmented negative-strand RNA viruses in these 
cell lines. Finally, our results strongly point out the importance of using multiple cell 
lines of different origin when antiviral efficacy and potency are examined for new as well 




   
2.6 Figures 
 
Figure 2: Effect of ribavirin on viral replication in seven cell lines. (A) The organization 
of the negative-sense RNA genomes of the recombinant viruses used in this study. (B) 
The panels show photographs of cells pretreated for 24 h with increasing concentrations 
of ribavirin as indicated (or mock-treated), infected with VSV-GFP (left) or SeV-GFP 
(right) at MOI 3 CIU/cell (or mock-infected, upper row), and then the same 
concentrations of drugs as in the pretreatment was added to each well after virus 
absorption. Fluorescence (upper panels) and light (lower panels) microscopy images were 
captured at 10× magnification. The photographs are typical representations of at least 
three independent experiments and an average field for each well is shown. (C) Media 
from the experiments described in B was collected at 24 h p.i for VSV (left) or at 48 h p.i 
for SeV (right) and virus titer was determined by standard plaque assay on BHK21 (for 
VSV) or Vero cells (for SeV). The data represent the mean ± standard deviation of two 
independent experiments (done in duplicates). Statistical analysis was done using one-
way ANOVA with Tukey's post hoc test (GraphPad Prism 4, San Diego, CA). ribavirin 
treatments without significant decrease in viral titer at any tested ribavirin concentrations 
as compared to mock-treated cells (“0 µM ribavirin”) are indicated as P>0.05. 
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2.6 Figures continued 
 
Figure 3. Effect of ribavirin 
on cell viability of seven cell 
lines. 
To determine the relative 
toxicity of increasing 
concentrations of ribavirin in 
different cell lines, 80%-
confluent uninfected cells 
were treated with ribavirin 
for 24 h and tested for 
viability using MTT cell 
viability assay (A) or 
CellTiter-Glo Luminescent 
Cell Viability Assay (B) or 
by cell counting using trypan 
blue dye exclusion as an 
indicator of live cells (C) as 
described in Materials and 
Methods. To determine the 
sensitivity of the MTT assay, 
serial dilutions of A549 and 
HeLa cells were plated 
[lower left and right graphs in 
(A)], grown for 24 h, cells 
from separate wells were 
trypsinized and counted using 
a hemocytometer), and MTT 
assay was conducted as 
described in Materials and 
Methods. (A–C) The data 
(done in triplicate) represent 
the mean ± standard 
deviation and are expressed 
as a percentage of the 
untreated control. Statistical 
analysis was done using one-
way ANOVA with Tukey's 
post hoc test (GraphPad 
Prism 4, San Diego, CA). 
***P<0.001, **P<0.01, 
*P<0.05, as compared to 
mock-treated cells (indicated 





   
2.6 Figures continued 
 
 
Figure 4.  Plaque 




Cell monolayers were 
infected with VSV-
GFP or SeV-GFP (or 
mock-infected; 0 µM 
ribavirin) using virus 
dilutions producing 
about 100 virus 
(“100%”) on each cell 
line in the absence of 
ribavirin, overlaid 
with SFM containing 
1.2% Avicel RC-581 
and increasing 
concentrations of 
ribavirin (note that 
different ribavirin 
concentrations were 
used for each virus-
cell type 
combination). Cells 
were then incubated 
for 24 h (VSV) or 48 
h (SeV), and plaques 
were counted with the 
aid of fluorescence 
and bright field 
microscopy. “0%” 
indicates that no 
fluorescent infectious 
foci were detected. 
Each experiment was 
performed at least 
twice (done in 
duplicates) and data 
points represent the 





   
2.6 Figures continued 
 
Figure 5. Ribavirin uptake and its inhibition in different cell lines. (A) Cell monolayers 
on 24-well plates (done in triplicates) were pretreated for 15 minutes with 15 or 100 µM 
NBMPR/DMSO or mock-treated with the same amount of DMSO as contained in the 
treated wells. Cells were then treated with SFM containing 50 µM ribavirin 1% of which 
was [
3
H]ribavirin for 15 minutes at 37°C. Nucleotide pools were isolated and measured 
for [
3
H]. Uptake values represent CPM divided by number of cells in a 24-well plate and 
normalized to the uptake by DMSO-treated BHK21 cells (defined as 100%). The mean ± 
standard deviation is shown for four independent experiments. (B) Cell monolayers (done 
in triplicates) on 12-well plates were treated with SFM containing 50 µM ribavirin 1% of 
which was [
3
H]ribavirin at 37°C for 1 h, 16 h or 24 h. Nucleotide pools were isolated and 
measured for [
3
H]. Uptake values represent CPM divided by number of cells in a 12-well 
plate and normalized to the uptake by BHK21 cells for 1 h (defined as 100%). (A–B) 
Statistical analysis was done using one-way ANOVA with Tukey's post hoc test 
(GraphPad Prism 4, San Diego, CA). ***P<0.001, **P<0.01, *P<0.05, as compared to 
ribavirin only treated cells (A) or cells treated with ribavirin for 1 h (B). 
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2.6 Figures continued 
 
Figure 6. Effect of exogenously added guanosine on antiviral activity of ribavirin. Cells 
were mock infected or infected with either VSV-GFP or SeV-GFP at MOI of 3 CIU/cell, 
and then mock-treated or treated with SFM containing 500 µM ribavirin, 50 µM 
guanosine, or both. The intensity of GFP fluorescent signal at 18 h p.i for VSV (A) and 
24 h p.i for SeV (B) was quantified using a 96-well plate reader, as described in Materials 
and Methods. Each of these experiments was performed twice (done in triplicates) and 
data points represent the mean ± standard deviation. (A–B) Statistical analysis was done 
using one-way ANOVA with Tukey's post hoc test (GraphPad Prism 4, San Diego, CA). 
***P<0.001, **P<0.01, *P<0.05 are shown to compare ribavirin plus guanosine 
treatment against ribavirin treatment only. 
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2.6 Figures continued 
 
 
Figure 7. Effect of ActD 
on antiviral activity of 
ribavirin. Cell 
monolayers were 
infected with SeV-GFP 
(A) or VSV-GFP (B) at 
MOI 3 CIU/cell in the 
absence of drugs, or with 
5µg/ml ActD, 500 µM 
ribavirin, or both. 
Fluorescence (upper 
panels) and light (lower 
panels) microscopy 
images were captured at 
10× magnification. The 
photographs are typical 
representations of at least 
three independent 
experiments and an 
average field for each 
well is shown. (C) The 
number of new 
infectious VSV-GFP 
particles generated in the 
wells photographed in 
(B) was determined by 
analysis of SFM 
collected from each well 
by plaque assay on 
BHK21 cells (done in 





   
2.6 Figures continued 
 
Figure 8. Viral infectivity and replication kinetics in the seven cell lines. (A) Cells were 
infected with serial dilutions of VSV-GFP (left) or SeV-GFP (right), and infectious foci 
were counted to calculate the infectivity of the viral stock for each cell line. (B) One-step 
kinetics of viral replication in seven cell lines. Cells were infected in parallel with VSV-
GFP or SeV-GFP at MOI of 3 CIU/cell (1 h absorption), washed 3 times with PBS, and 
kept in SFM. The media containing newly generated virions was collected at the 
indicated time points and viral titrations were performed on BHK21 (for VSV) or Vero 












Table 2. Relative number of infectious virus particles added to different cell lines to 
achieve MOI 3 for each virus/cell combination. Most experiments in this study were 
conducted using 24-well tissue culture plates and nearly 100% confluent cells treated with 
ribavirin in SFM (or mock- treated with SFM) and infected with VSV-GFP or SeV-GFP (or 
mock-infected with SFM) at MOI of 3 CIU/cell of the tested cell line. The MOI of 3 
CIU/cell for each virus/cell type combination was calculated by infecting each cell line with 
serial dilutions of VSV-GFP or SeV-GFP virus stock in SFM and counting infectious foci 
with the aid of fluorescence microscopy (see Figure 8A). VSV CIU
BHK
 - number of cell 
infectious units (infectious particles) determined by titration of VSV-GFP virus stock on 
BHK21 cells. SeV CIU
HeLa
 - number of cell infectious units calculated by titration of SeV-

















   
 




Table 3. Antiviral activity (IC50 and IC90) of ribavirin against VSV and SeV in different 
cell types. The 50% and 90% inhibitory concentrations (IC50 and IC90) for ribavirin were 
estimated by means of the plaque reduction (Fig. 4) as described in Materials and 
Methods. Data are expressed as mean without standard error of mean that, however, 
never exceeded 20% of the mean values. Note that an extremely poor potency of ribavirin 









CHAPTER 3: RESISTANCE OF PANCREATIC CANCER CELLS TO ONCOLYTIC 




VSV as an anticancer agent against pancreatic ductal adenocarcinoma. 
 Pancreatic ductal adenocarcinoma (PDA) is the most common form of pancreatic 
cancer and accounts for more than 85% of all pancreatic malignancies. PDAs are highly 
invasive and rapidly metastasized to different tissues (Stathis A and Moore 2010). Due to 
poor prognosis the survival rate of patients for more than 5 years is less than 5%.  A 
majority of patients die between 4-6 months after initial diagnosis (Jemal, Siegel et al. 
2010). PDA initiates with alterations in oncogenes and tumor suppressor genes, which 
leads to a series of pre-invasive stages of PDA known as pancreatic intraepithelial 
neoplasias (PanINs). These PanINs eventually results in metastatic invasive PDA 
(Farrow B, Albo D et al. 2008). These lesions recruit different immune cells to these sites 
resulting in a massive local inflammatory response. This results in recruitment of 
regulatory T cells, myeloid derived suppressor cells (MDSCs) for immunosuppression 
and this immune-privilege leads to the establishment of devastating disease (Farrow B, 
Albo D et al. 2008). 
A complete surgical resection of tumor is the only curative treatment available at 
this time for PDA. Even with surgical resection only 15–20% patients have the survival 
rate of greater than 5 years. Even though there has been important development in 
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understanding the molecular mechanisms of PDA regulation, alternative therapies are 
urgently needed (Jones, Zhang et al. 2008; Jemal, Siegel et al. 2010).  
 
Figure 9. Schematics of a typical oncolytic virotherapy. (Figure is used with the 
permission from Dr. Andrea Murphy) 
 
 In 1893 it was first observed that some patients suffering from cancer infected 
with viruses exhibited signs of tumor regression (Kelly and Russell 2007; Sinkovics JG 
and and Horvath 2008). This observation led to scientific research into the development 
of oncolytic virus (OV) therapy. OV therapy is a relatively new emerging therapeutic 
option, where specifically tumor cells are being targeted and killed by viruses without 
infecting healthy cells. Such selectivity is achieved due to the fact that many cancer cells 
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have defective innate immune responses or deregulation of other signaling pathways to 
facilitate the replication of viruses selectively in cancer cells (Vaha_Koskela, Tuittila et 
al. 2003; Breitbach, Reid et al. 2010; Hastie and Grdzelishvili 2012). Defective innate 
immune responses, such as defects in type 1 IFN response is advantageous for tumor 
growth, however it makes them more susceptible for selective viral infection (Stojdl, 
Lichty et al. 2000; Naik and Russell 2009; Hastie and Grdzelishvili 2012; Murphy, 
Besmer et al. 2012).  
Many viruses have been evaluated for their ability to specifically target cancer 
cells against various kinds of tumors including reovirus, Newcastle disease virus, mumps 
virus, measles virus, adenovirus, VSV, vaccinia virus, Herpes simplex virus etc. Viruses 
which require specific surface markers or nuclear transcription factors expressed 
exclusively by specific cancer cells can selectively kill those tumor cells. Alternatively, 
specific oncolytic viruses can be genetically engineered which can exclusively infect and 
kill various tumor cells by exploiting their defective antiviral immune responses (Russell, 
Peng et al. 2012). 
 Several characteristics of VSV make it a promising OV against various types of 
cancers. Compared with other viruses for oncolytic virotherapy, VSV has some obvious 
advantages. VSV biology is very well studied and VSV is relatively independent of any 
host receptor for infection and cell cycle. VSV can be easily propagated to very high titer 
and infect a majority of cell lines from various hosts and origin (Barber 2004). Moreover, 
VSV replicates within the cytoplasm, which prevents the risk of any host cell 
transformation. Human also do not possess any pre-existing immunity against VSV. The 
relatively small genome of VSV can be easily manipulated to make a better more 
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efficient and safer oncolytic VSV (Barber 2004; Hastie and Grdzelishvili 2012). Similar 
to other OVs, there are some limitations that need to be overcome to make VSV a 
successful candidate for future clinical successes.    
In the past decade a great number of recombinant VSVs (rVSV) have been 
developed by different laboratories to make more efficient OVs to reduce tumor burden 
without infecting healthy cells of hosts. Currently, several approaches have been utilized 
to improve the safety and oncoselectivity of VSV as an OV.  The most common and most 
popular approach employs mutating VSV M protein, which is required by VSV to evade 
the antiviral innate immune responses by non-cancerous normal host cells. VSV M 
protein mutants retain their ability to kill tumor cells by improving their oncoselectivity 
and safety. Most studies have used a VSV M mutant with mutation or deletion of 
methionine at 51
st
 position of the M protein. In our study we used the VSV with the 
deletion at 51
st
 position of M protein and the green fluorescent protein (GFP) in the viral 
genome for the easy monitoring of virus infection. This strain will be referred to as VSV-
Δ-M51-GFP throughout the dissertation. This mutation results in the prevention of 
binding M protein with the Rae1-Nup98 mRNA complex. This interaction is critical for 
VSV to inhibit the transport of cellular mRNA from nucleus to cytoplasm (Petersen, Her 
et al. 2000) and a major mechanism through which VSV evaded the host innate immune 
responses (Hastie and Grdzelishvili 2012). VSV M mutants are unable to block this 
transport making them extremely susceptible to host antiviral responses and thus provide 
enhanced safety including lack of neurotoxicity in vivo. Moreover, this added feature 
makes VSV a better OV because a majority of tumors are known to have defective innate 
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immune responses and VSV-Δ-M51 can selectively kill tumor cells with improved 
safety. 
Role of host type I IFN responses in resistance to OV therapy. 
 A previous study from our laboratory demonstrated for the first time that VSV is a 
promising oncolytic agent against PDA (Murphy, Besmer et al. 2012). In this study a 
majority of tested PDA cell lines were susceptible to VSV-Δ-M51-GFP infection and 
efficiently killed by virus infection. However, five PDA cell lines showed resistance to 
VSV-Δ-M51-GFP infection at least at low multiplicity of infection (MOI) (Murphy, 
Besmer et al. 2012). One of the resistance cells chosen for in vivo experiments exhibited 
the same phenotype as in vitro and tumor burden was not reduced compared to VSV-Δ-
M51-GFP susceptible cell line. Resistance to oncolytic VSV infection has been reported 
with other cancer cell types including prostate cancer, bladder cancer, sarcoma, chronic 
lymphosytic leukemia (Carey, Ahmed et al. 2008; Tumilasci, Oliere et al. 2008; Zhang, 
Matsui et al. 2010; Janelle, Brassard et al. 2011; Paglino and van den Pol 2011). Many 
studies have provided evidences which suggest that resistance to OV therapy is mainly 
host driven and not virus driven. For example, a synovial sarcoma cell line was found to 
be resistant to three very different viruses including VSV-Δ-M51, Sindbis virus and 
cytomegalovirus (CMV) (Paglino and van den Pol 2011). Previous study from our 
laboratory also evaluated the oncolytic potential of variants of VSV, RSV, SeV and 
conditionally replicative adenoviruses (CRAds) in 13 PDA cells and found that some 
PDA cells are resistant to all of these viruses (Murphy, Besmer et al. 2012). These data 
suggests that host factors play a key role in determining the oncolytic potential and 
success of OV therapy.  
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There are various mechanisms of resistance to VSV oncolysis that have been 
noted, including intact type I IFN response or defective apoptosis pathway in tumor cells 
(Gaddy DF and and Lyles 2005; Monsurro, Beghelli et al. 2010; Paglino and van den Pol 
2011). However, it is widely accepted that the sensitivity to type I IFN by tumor cells is 
the major mechanism of oncolytic VSV resistance (Le Boeuf, Diallo et al. 2010; Paglino 
and van den Pol 2011; Moerdyk-Schauwecker, Shah et al. 2012).  Previously our lab 
demonstrated that compared to VSV susceptible PDA cells, VSV resistant PDA cells 
both produced and responded to type I IFN signaling (Murphy, Besmer et al. 2012). In 
contrast to these results it is commonly believed that most cancer cells have defective 
type I IFN responses, because intact type I IFN response negatively affects tumor 
development (Barber 2004; Lichty BD, Power AT et al. 2004; Murphy, Besmer et al. 
2012). Type I IFN responses are usually anti-angiogenic, anti-proliferative and pro-
apoptotic (Wang, Rahbar et al. 2011). Despite of these, various cancer cells have been 
shown to synthesize or respond to type I IFN including lymphomas (Sun, Pabon et al. 
1998), melanomas (Linge, Gewert et al. 1995; Wong, Krauer et al. 1997) , bladder cancer 
(Matin, Rackley et al. 2001) , mesotheliomas (Saloura, Wang et al. 2010), renal 
cancer(Pfeffer, Wang et al. 1996) and probably other cancers (Stojdl DF 2003).  
OVs targeting different signaling pathways to mount a strong attack against tumor 
cells can enhance the cancer therapy drastically. A number of studies with various 
cancers have shown that elevated levels of certain ISGs are directly responsible for the 
resistance to various viruses. These ISGs are usually upregulated through the type I IFN 
induced JAK-STAT signaling (Fig 10).  Moreover, a few studies of OV resistant cell 
culture model of prostate cancer and sarcomas have demonstrated that reducing the level 
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of these ISGs can enhance the susceptibility to OV (Carey, Ahmed et al. 2008; Paglino 
and van den Pol 2011). The reduction of ISGs has shown to be achieved by pre-treating 
cells with the inhibitor of JAK-1 (JAK Inh I) (Paglino and van den Pol 2011), with 
histone deacetylase inhibitor valproic acid (VPA) (Hoti, Chowdhury et al. 2006; Paglino 
and van den Pol 2011; Watanabe, Hashimoto et al. 2012) or with vaccinia viral protein 
B18R (Le Boeuf, Diallo et al. 2010; Paglino and van den Pol 2011) . Treatment with JAK 
Inh. I, VPA or vaccinia viral protein B18R can attenuate the type I IFN signaling 
(Paglino and van den Pol 2011).  
 
 
Figure 10. The type I IFN signaling cascade showing synthesis of ISGs. 
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In this study, we hypothesized that constitutive expression of specific ISGs is 
mainly responsible for the resistance of PDA to oncolytic VSV and the resistance can be 
overcome by selective inhibition of the type I IFN signaling.  To test this hypothesis the 
role of type I IFN signaling in the resistance to oncolytic VSV has been investigated in 
many PDA cells. Moreover, we also determined whether the PDA cells resistant to VSV-
Δ-M51-GFP can become more susceptible to infection when treated with inhibitor of 
type I IFN signaling.  To overcome the resistance of specific PDA cells to oncolytic VSV 
infection, it is extremely important to find the host factors responsible for such 
phenotypes. Because, type I IFN response is mainly responsible for such resistance, 33 
genes involved with type I IFN response were evaluated for the expression of mRNA. 
Our data clearly demonstrated that at least two host factors MxA and OAS (known 
antiviral genes) were constitutively expressed in only VSV-Δ-M51-GFP resistant cells 
(Fig. 10).  
These results also correlated with the protein expression data for both genes. Our 
data also indicated that in virus infected cells the reduced levels of MxA and OAS 
correlate with the increased susceptibility to VSV-Δ-M51-GFP infection. Even though 
we demonstrated that a role of type I IFN responses in the resistance of PDA cells to 
VSV-Δ-M51-GFP infection, it is possible that other cellular factors may influence the 
susceptibility of VSV-Δ-M51-GFP to various PDA.  
Overall, our results demonstrate the importance and practical implications of 




   
 
3.2 Introduction 
Oncolytic virus (OV) therapy utilizes viruses with naturally inherited or 
engineered properties enabling them to preferentially infect and kill cancer cells (Russell 
and Peng 2007; Vähä-Koskela MJ, Heikkilä JE et al. 2007; Breitbach, Reid et al. 2010). 
This approach utilizes common cancer characteristics such as defective innate immune 
responses or abnormalities in regulation of mRNA translation or cellular signaling 
pathways to provide the needed cancer specificity.  
Vesicular stomatitis virus (VSV) has been successfully used as an OV in 
preclinical models of a number of malignancies [reviewed in (Barber 2004; Hastie and 
Grdzelishvili 2012)]. As a result, a clinical trial using VSV against hepatocellular 
carcinoma is currently in progress (Clinicaltrials.gov, 2012, Trial ID: NCT01628640). A 
number of oncolytic VSV recombinants have been developed to address safety concerns 
relating to the use of wild-type (wt) VSV.  In one of these, VSV-∆M51-GFP, a deletion 
of the methionine at amino acid position 51 of the matrix (M) protein prevents shut down 
of cellular gene expression (Ahmed, McKenzie et al. 2003), providing enhanced safety, 
including an absence of neurotoxicity in vivo, while still demonstrating good oncolytic 
potential (Stojdl DF 2003; Ebert O, Harbaran S et al. 2005; Goel, Carlson et al. 2007; 
Ahmed M 2008; Wu L 2008; Kelly EJ, Nace R et al. 2010; Wollmann G 2010). 
We recently tested wild-type (wt) VSV and two non-neurotropic VSV 
recombinants (including VSV-∆M51-GFP), as well as recombinant Sendai virus, 
recombinant respiratory syncytial virus and two recombinant adenoviruses against a 
panel of human pancreatic ductal adenocarcinoma (PDA) cell lines (Murphy, Besmer et 
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al.). PDAs are highly aggressive and metastatic (Stathis A and Moore 2010) and 
represent about 95% of pancreatic cancers. PDA is one of the most lethal abdominal 
malignancies (Lindsay TH, Jonas BM et al. 2005; Farrow B, Albo D et al. 2008), and 
current treatments are largely ineffective (Stathis A and Moore 2010). Our study 
demonstrated VSV is a promising oncolytic agent against PDA, as the majority of PDA 
cell lines tested were highly susceptible to infection and killing by VSV recombinants 
(Murphy, Besmer et al.).  However, five PDA cell lines as well as the non-malignant 
HPDE cell line were resistant to most VSV recombinants, (wt VSV, VSV-∆M51-GFP, 
and VSV-p1-GFP), at least at low multiplicities of infection (MOI), the expected scenario 
in vivo. 
Unlike permissive PDA cell lines, most resistant PDA cell lines were able to both 
secrete and respond to type I interferon (IFN), suggesting intact type I IFN responses 
contributed to their resistance phenotype (Murphy, Besmer et al.).  While other 
mechanisms have been noted (Barber 2004; Hastie and Grdzelishvili 2012), type I IFN 
sensitivity is believed to be a major factor contributing to VSV’s oncoselectivity, as it is 
unable to efficiently infect healthy cells.  In contrast, the majority of cancer cells are 
thought to be defective in type I IFN production and responses (Barber 2004; Lichty BD, 
Power AT et al. 2004; Hastie and Grdzelishvili 2012), as IFN responses are generally 
anti-proliferative, anti-angiogenic and pro-apoptotic (Wang, Rahbar et al. 2011), 
conditions unfavorable for tumor formation.  However, some cancer cells are known to 
produce and/or respond to type I IFN (Stojdl, Lichty et al. 2000; Naik and Russell 2009), 
including some mesotheliomas (Saloura, Wang et al. 2010), melanomas (Linge, Gewert 
et al. 1995; Wong, Krauer et al. 1997), lymphomas (Sun, Pabon et al. 1998), bladder 
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cancers (Matin, Rackley et al. 2001), renal cancers (Pfeffer, Wang et al. 1996), and 
possibly other cancers (Stojdl DF 2003).   
Here we further analyze a panel of 11 clinically relevant human PDA cell lines for 
the presence of type I IFN response, determine the functionality of that response in 
resistance to VSV-∆M51-GFP and attempt to identify an RNA and/or protein which 
presence or absence was well correlated with resistance to this virus.  The cell lines most 
resistant to VSV-∆M51-GFP infection were shown to constitutively express at least some 
interferon stimulated genes (ISGs), including the antiviral genes MxA and OAS. 
Inhibition of the JAK/STAT signaling pathways reduced ISG expression and improved 
VSV-ΔM51-GFP infectivity, replication and oncolysis, implicating IFN responses in 
resistance. 
Apart from type I IFN signaling, other mechanisms have been implicated to 
induce ISGs. For example ISGs can be upregulated by activation of NF-κB pathway 
(Basagoudanavar, Thapa et al. 2011), via chromatin modification (Paglino and van den 
Pol 2011) or through IFN-λ signaling. Our laboratory has planned to explore these other 
mechanisms of ISG stimulation in future.  I am currently investigating the potential role 








   
3.3 Materials and Methods: 
Cell lines. 
The human PDA cell lines used in this study were: AsPC-1 (ATCC CRL-1682), 
Capan-1 (ATCC HTB-79), Capan-2 (ATCC HTB-80), CFPAC-1 (ATCC CRL-1918), 
HPAC (ATCC CRL-2119), HPAF-II (ATCC CRL-1997), Hs766T (ATCC HTB-134), 
MIA PaCa-2 (ATCC CRL-1420), Panc-1 (ATCC CRL-1469), Suit2 (Iwamura T, Katsuki 
T et al. 1987) and T3M4 (Okabe T, Yamaguchi N et al. 1983). In addition, a non-
malignant human pancreatic duct epithelial (HPDE) cell line (Furukawa T, Duguid WP et 
al. 1996) was used and maintained in Keratinocyte-SFM (K-SFM, Gibco). This cell line 
was generated by introduction of the E6 and E7 genes of human papillomavirus 16 into 
normal adult pancreas epithelium, retains a genotype similar to pancreatic duct 
epithelium and is non-tumorigenic in nude mice (Furukawa T, Duguid WP et al. 1996). 
The mouse breast cancer cell line 4T1 (ATCC CRL-2539), baby hamster kidney BHK-21 
fibroblasts (ATCC CCL-10) and African green monkey kidney Vero cells (ATCC CCL-
81) were used to grow viruses and/or as controls. Capan-1, CFPAC-1, HPAC, MIA 
PaCa-2, Panc-1, Suit2, 4T1 and Vero cells were maintained in Dulbecco's modified 
Eagle's medium (DMEM, Cellgro).  AsPC-1, Capan-2 and T3M4 cells were maintained 
in RPMI 1640 (HyClone). HPAF-II and BHK-21 cells were maintained in modified 
Eagle's medium (MEM, Cellgro).  All cell growth media were supplemented with 9% 
fetal bovine serum (FBS, Gibco), 3.4 mM L-glutamine, 900 U/ml penicillin and 900 
µg/ml streptomycin (HyClone).  MEM was further supplemented with 0.3% glucose 
(w/v).  K-SFM was never supplemented with serum.  Cells were kept in a 5% CO2 
atmosphere at 37°C.  For all experiments, PDA cell lines were passaged no more than 10 
times 
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Viruses. 
The following viruses were used in this study: VSV-ΔM51-GFP, vaccinia virus 
expressing T7 (VVT7) and herpes simplex virus type 1 (HSV-1) (MacIntyre strain; 
ATCC, VR-539).  VSV-ΔM51-GFP has a deletion of methionine at amino acid position 
51 of the M protein and the green fluorescent protein (GFP) ORF inserted at position 5 of 
the viral genome (Wollmann G 2010).  VVT7 was created by integration of the 
bacteriophage T7 RNA polymerase into the vaccinia virus (strain Western Reserve) 
thymidine kinase gene (Fuerst, Niles et al. 1986/11).  VSV-ΔM51-GFP was grown on 
BHK-21 while VVT7 and HSV-1 were grown on Vero.  Viral titers were determined by 
standard plaque assay on 4T1 and/or Vero cells and expressed as cell infectious units 
(CIU) per ml.   
RNA analysis. 
Cells were either mock-treated, infected with VSV-∆M51-GFP at MOI of 10 CIU 
per cell (based on 4T1) or treated with 5,000 U/ml IFN-α (Calbiochem, 407294).  Total 
RNA was extracted from cells at 4 or 12 hours (h) post-infection (p.i.) using the Quick-
RNA Mini Prep kit in accordance with manufacturer instructions (Zymo Research). 0.5 
μg of total RNA per reverse transcription (RT) reaction using SMARTScribe reverse 
transcriptase (Clontech) was used for the cDNA synthesis as per manufacturer’s protocol. 
PCR was carried out on this cDNA using the following conditions:  denaturation at 94°C 
for 45 seconds (s), annealing at 57°C for 45 s, extension at 72°C for 45 s for either 25, 30 
or 35 cycles and a finishing step at 72°C for 8 min. All primers for PCR are shown in the 
Table 7 and were designed to not amplify genomic DNA. PCR products were 
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electrophoresed on a 2% agarose gel with ethidium bromide and photographed using a 
GelDoc-It imager (UVP imaging, Upland, CA). 
Western blot. 
Cellular lysates were prepared from cells either mock-treated, infected with VSV-
∆M51-GFP at MOI 10 CIU/cell (based on 4T-1) or treated with 5,000 U/ml IFN-α. At 1 
h p.i., virus was aspirated and cells were extensively washed and incubated in growth 
media containing 5% FBS. Cells were harvested at 12 h p.i. and lysed in lysis buffer (pH 
7.5) containing 1% Triton-X-100, 20mM Hepes, 0.15 M NaCl, 2 mM EDTA and 
supplemented with c-inhibitor (2X, Roche) and Phosphatase Inhibitor Cocktail 2 (Sigma-
Aldrich).  Total protein concentration was determined by Bradford assay.  Twenty µg of 
total protein was separated by electrophoresis on 10% SDS-PAGE gels and electroblotted 
to polyvinylidene difluoride (PVDF) membranes.  Membranes were blocked using 5% 
non-fat powdered milk in TBS-T [0.5 M NaCl, 20 mM Tris (pH 7.5), 0.1%Tween20]. 
Membranes were incubated with 1:5000 rabbit polyclonal anti-VSV antibodies (raised 
against VSV virions), 1:1000 rabbit anti-MX1 (Sigma-Aldrich, SAB1100070), 1:200 
rabbit anit-OAS2 (Santa Cruz, sc-99097), 1:3000 mouse anti-GFP (Rockland, 600-301-
215), and the following antibodies from Cell Signaling (1:1000): anti-STAT1 (9172), 
Stat1-P (9171), Stat2 (4594), Stat2-P (4441), IRF3 (4302), IRF3-P (4947), eIF2α (5324), 
and eIF2α-P (3398) in TBS-T with 5% BSA.  Detection was with 1:2000 goat anti-rabbit 
or 1:5000 goat anti-mouse horseradish peroxidase-conjugated secondary antibodies 
(Jackson ImmunoResearch, 111-035-003 and 115-035-003, respectively) using the 
Enhanced Chemiluminescence Plus (ECL+) protein detection system (GE Healthcare). 
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Membranes were reprobed with mouse anti-actin antibody (clone C4) (Moyer, Baker et 
al. 1986/8) to verify sample loading.   
JAK Inhibition. 
For new infectious particle production, 6-well plates were seeded such that they 
were approximately 80% confluent at the time of inhibitor treatment.  Cells were 
pretreated with 0.5 or 2.5μM JAK inhibitor I (Jak Inh I, Calbiochem) or vehicle (DMSO) 
only in cell culture media with 5% FBS (K-SFM was used without FBS) for 48 h prior to 
infection (media was removed and replaced with fresh drug/vehicle containing media 
after the first 24 h).  Cells were then mock infected or infected with VSV-ΔM51-GFP in 
DMEM without FBS at an MOI of 10 CIU/cell (based on 4T1).  Following a 1 h 
absorption period, the virus containing media was aspirated, cells were washed three 
times with PBS and growth media with 5% FBS containing either 0.5 or 2.5μM JAK Inh. 
1 or vehicle was added to the wells.  At 16 h p.i., media was collected and used for a 
standard plaque assay on BHK-21 cells.  Cells treated and infected in the same manner 
were also used to prepare cellular lysates for western blotting as described above. 
For plaque and cell viability assays, cells were seeded in 96-well plates such that 
they were approximately 80% confluent at the time of inhibitor treatment, and pretreated 
for 48 h with JAK Inh. I as described above.  For the plaque assay, cells were then 
infected with 8-fold serial dilutions of VSV-ΔM51-GFP in DMEM without FBS.  
Following a 1 h absorption period, the virus containing media was aspirated and replaced 
with cell culture media containing 5% FBS and either JAK Inh I or vehicle.  At 17 h p.i., 
fluorescent foci were visualized and counted using fluorescent microscopy.  For the cell 
viability assay, following pretreatment, cells were mock infected or infected with VSV-
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ΔM51-GFP in DMEM without FBS at a MOI of 1 CIU/cell (based on 4T1). Following a 
1 h absorption period, the virus containing media was aspirated and replaced with growth 
media with 5% FBS containing either 0.5 or 2.5 μM JAK Inh. 1 or vehicle. GFP 
fluorescence was measured every 24 h using a CytoFluor multi-well plate reader 
(PerSeptive Biosystems) with excitation filter of 450/50nm, emission filter of 530/25nm 
and gain=50.   At 5 days (d) p.i., cell viability was analyzed using a 3-(4,5-dimethyl-2-
thiazolyl)-2,5- diphenyl-2H-tetrazolium bromide (MTT) cell viability assay (Biotium) in 
accordance with manufacturer instructions.  
Permissiveness of cells to different viruses. 
Cells were seeded in 24-well plates such that they were approximately 90% 
confluent at the time of infection.  Cells were infected with 8-fold serial dilutions of 
VSV-∆M51-GFP, VVT7, or HSV-1 in DMEM without FBS for 1 h. Virus was aspirated 
and cells were overlaid with the appropriate growth media containing 5% FBS and 0.5% 
BactoAgar. For VSV-∆M51-GFP, fluorescent foci were visualized at 3 d p.i. by 
fluorescent microscopy.  For all viruses, at 5 d p.i. cells were fixed by addition of 350 µl 
10% neutral buffered formalin (Sigma-Aldrich) to each well. Following 1 h incubation at 
room temperature, the agar was gently removed and cells stained with 1% crystal violet 
in 20% methanol to allow visualization of plaques. 
Cell viability following infection with different viruses. 
Cells were seeded in 96-well plates such that they were approximately 80% 
confluent at the time of infection.  Cells were mock infected or infected with VSV-
∆M51-GFP, VVT7, or HSV in SFM-MegaVir, at an MOI of 1 or 0.01 CIU/cell (based on 
Vero). Following a 1 h absorption period, the virus containing media was aspirated and 
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replaced with growth media containing 5% FBS.  At 5 d p.i., cell viability was analyzed 
using an MTT cell viability assay (Biotium) in accordance with manufacturer 
instructions. 
Statistical Analysis. 
All statistical analyses were performed using GraphPad Prism, version 5.03 for Windows 
(GraphPad Software, San Diego, California).  Comparisons within a cell line following 


















   
3.4 Results  
Identification of antiviral genes constitutively expressed in PDA cells resistant to 
VSV. 
Our recent evaluation of VSV against human PDA cell lines revealed substantial 
diversity in their susceptibility to VSV-mediated oncolysis, which correlated with 
permissiveness to VSV infection (Murphy, Besmer et al.). Most resistant PDA cell lines 
were both sensitive to IFN-α treatment (which strongly inhibited VSV infection) and 
capable of secreting IFN-β following VSV infection (Murphy, Besmer et al. 2012), 
suggesting resistant PDA cell lines may retain active type I IFN signaling.  In this study, 
we assessed type I IFN related cellular responses to VSV-∆M51-GFP infection on a 
molecular level in a panel of 11 clinically relevant human PDA cell lines (Table 4), and 
examined the role of the JAK/STAT signaling pathways in the observed resistance 
phenotypes. 
Expression of 33 human genes (Table 7) responsible for sensing viral infection 
[e.g. retinoic-acid-inducible gene I (RIG-I)], activating production of type I IFNs [e.g. 
IFN-regulatory factor (IRF) 3], sensing IFNs [e.g. interferon alpha/beta receptor 1 
(IFNAR1)] and inducing an antiviral state in cells [e.g. myxovirus (influenza) resistance 
1 (MxA)] was assessed. Since we wanted to focus on a specific set of genes, this was 
done using semi-quantitative RT-PCR.  Genes were selected based on their importance in 
type I IFN responses.  Some of these genes, particularly ISGs, are expressed in response 
to type I IFNs, and are expected to be upregulated in cells with intact type I IFN signaling 
following VSV infection.  Also, differential expression of RIG-I (Wilden, Fournier et al. 
2009), myeloid differentiation primary response protein MyD88 (MyD88) (Wongthida, 
Diaz et al. 2011), IRF3 (Marozin, Altomonte et al. 2008; Wilden, Fournier et al. 2009), 
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IRF7 (Wilden, Fournier et al. 2009) IFNAR1/2 (Saloura, Wang et al. 2010; Zhang, 
Matsui et al. 2010), tyrosine-protein kinase JAK1 (JAK1) (Dunn, Sheehan et al. 2005), 
signal transducer and activator of transcription (STAT) 1 (Lee, Bluyssen et al. 1997; Sun, 
Pabon et al. 1998), IRF9 (Matin, Rackley et al. 2001; Saloura, Wang et al. 2010), MxA 
(Monsurro, Beghelli et al. 2010; Paglino and van den Pol 2011), 2'-5'-oligoadenylate 
synthetase (OAS) (Monsurro, Beghelli et al. 2010; Saloura, Wang et al. 2010), and 
interferon-induced, double-stranded RNA-activated protein kinase (PKR) (Saloura, Wang 
et al. 2010) has been previously reported to correlate to or be responsible for the virus or 
IFN resistance phenotypes of various cancer cell types.  
PDA cells were mock infected or infected with VSV-∆M51-GFP for 4 h, and total 
RNA was isolated and analyzed for expression of candidate genes.  As shown in Figure 
11, most analyzed genes (including all additional genes listed in Table 7 but not shown in 
Figure 11) were expressed at similar levels in all cell lines regardless of the VSV 
resistance phenotype. However, several genes were clearly differentially expressed. 
Among genes associated with sensing viral infection, IRF7 was down regulated in 
Capan-1 and MIA PaCa-2, both highly susceptible to VSV-mediated cell death (Murphy, 
Besmer et al. 2012). In agreement with a key role for IRF7 in the expression of type I 
IFNs following viral infection (Honda, Yanai et al. 2005), these same two cell lines also 
lacked IFN-α and β gene expression even after VSV-∆M51-GFP infection (Fig. 11). 
Interestingly, reduced expression of IRF-7 has recently been linked to increased 
metastasis in breast cancer, with disruption of IFN signaling identified as the primary 
cause (Bidwell, Slaney et al. 2012). 
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Although in our previous study only 4 cell lines (HPAF-II, HPAC, Hs766T and 
non-malignant HPDE) produced detectable levels of secreted IFN-β at 18 h p.i. (Murphy, 
Besmer et al. 2012), here VSV-∆M51-GFP at 4 h p.i. induced production of IFN-β 
mRNA in all cell lines except Capan-1 and MIA PaCa-2 (Fig. 11). Most cell lines (again, 
with the exception of Capan-1 and MIA PaCa-2) also showed constitutive expression of 
IFN-α mRNA that was only marginally increased upon VSV-∆M51-GFP infection at 4 h 
p.i. The highest constitutive levels of IFN-α mRNA were seen in three of the resistant cell 
lines, HPAF-II, Hs766T and HPAC.  While differences in IRF7, IFN-α and IFN-β 
mRNA expression were observed, these alone could not discriminate between the 
phenotypes of PDA cells based on their permissiveness to VSV.  
As shown in Figure 11, differences were not seen in the expression of the IFN-
α/IFN-β receptor (IFNAR1 and IFNAR2), or the major components of IFN type I signal 
transduction (JAK1, STAT1, STAT2 and IRF9) at the transcriptional level. However, 
there was great variability in the expression of two ISGs, MxA and OAS. Importantly, 
there was a correlation between virus resistance phenotype and the levels of MxA and 
OAS mRNA.  MxA and OAS were at the highest levels in the resistant cell lines HPAF-
II, Hs766T, HPAC and non-malignant HPDE; at lower levels (especially in the absence 
of infection) in less resistant Suit2, T3M4 and CFPAC-1; and minimally produced in the 
remaining cell lines, all of which are highly susceptible to VSV-∆M51-GFP infection. 
Interestingly, while MxA and OAS had variable mRNA expression in different PDA cell 
lines a 4 h p.i., a similar pattern was not observed with other antiviral ISGs such as PKR, 
RNAse L, ISG56 and viperin. 
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To confirm the association of MxA and OAS expression with the resistance of 
PDA cells to VSV-∆M51-GFP, we conducted a similar experiment with a representative 
group of 7 cell lines mock-treated, treated with IFN-α, or infected with VSV-∆M51-GFP 
for 12 h to allow for accumulation of activated proteins. In this experiment (Fig. 12), we 
conducted not only mRNA analysis (as in Figure 11), but also western blot analysis to 
determine protein levels of the analyzed genes. In addition to the non-malignant HPDE, 
which has intermediate resistance, we analyzed two highly resistant (HPAF-II, Hs766T), 
one intermediate (HPAC) and three susceptible cell lines (MIA PaCa-2, AsPC-1, Suit2).  
Susceptibility to viral infection was confirmed based on virus-directed GFP expression, 
which we have previously shown correlates well with viral protein synthesis (Murphy, 
Besmer et al. 2012). Importantly, among susceptible cell lines, we selected two cell lines 
(AsPC-1 and Suit2) previously shown to be responsive to IFN-α treatment and one cell 
line (MIA PaCa-2) which was completely resistant to IFN-α treatment (Murphy, Besmer 
et al. 2012). As shown in Figure 12, a correlation was observed between MxA and OAS 
accumulation (mRNA and protein) and the resistance phenotype of PDA cell lines.  
Again, all resistant cell lines showed constitutive expression of MxA and OAS 
even in the absence of virus infection or IFN treatment.  The expression of MxA and 
OAS is controlled via STAT1 and STAT2 activation. Although variations in mRNA 
levels were not observed for STAT1 and STAT2 (Fig. 11 and 12), we tested whether 
phosphorylation of the protein products differed in VSV permissive and resistant cell 
lines. As shown in Figure 12, although most cell lines had detectable levels of 
phosphorylated STAT1 protein following 12-h IFN-α treatment, the highest levels of 
STAT1 activation following VSV-∆M51-GFP infection were observed in HPAF-II, 
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Hs766T and HPAC, all of which are resistant.  Also, lower but detectable levels of 
phosphorylated STAT1 in untreated cells were detected in these three cell lines and in 
HPDE, which may at least partially explain the constitutive expression of MxA and OAS 
in these cell lines. Among the susceptible cell lines, STAT1 was activated in AsPC-1 and 
to a much lesser degree in Suit2 upon infection, but not in MIA PaCa-2, although it was 
strongly activated in MIA PaCa-2 upon IFN treatment.  A similar pattern of protein 
phosphorylation was observed for STAT2 (Fig. 12). 
To test whether PDA cell lines susceptible to VSV-∆M51-GFP are able to detect 
VSV infection, we analyzed phosphorylation of IRF3.  Interestingly, all tested PDA cell 
lines showed increased IRF3 phosphorylation in response to infection (Fig. 12), 
suggesting the upstream components of the RIG-I pathway are functional.  In agreement 
with this observation, type III IFN-λ mRNA was expressed in all cell lines in response to 
VSV-∆M51-GFP infection (Fig. 11 and 12).  However, at 12 h p.i., MIA Paca-2 still 
failed to activated IFN-α and IFN-β mRNA expression.  
Key differences in mRNA and protein expression are summarized in Table 4 and 
Table 5 respectively.  Together, our gene expression data suggest all tested PDA cell 
lines are capable of sensing VSV infection, most produce type I IFNs, and most are 
capable of sensing IFN. However, resistant cell lines were characterized by constitutive 





   
Improved oncolysis of resistant PDA cells by combination treatment with JAK 
inhibitor I. 
Gene expression data showed a correlation between resistance to VSV-∆M51-GFP 
infection and elevated expression of at least some ISGs.  Therefore, a possible causative 
role for these and other ISGs in the resistance phenotype was tested by inhibition of the 
JAK/STAT signaling pathways responsible for activation of ISG expression, using a 
general inhibitor of JAKs, JAK Inh. I. First, the effectiveness of the JAK Inh I treatment 
was confirmed by western blot for p-STAT1, MxA and OAS. Twenty-four h treatment 
with 0.5 or 2.5μM JAK Inh I completely eliminated STAT1 phosphorylation and 
markedly reduced MxA and OAS protein levels.  The same treatments for 48 h, followed 
by mock infection or infection with VSV-∆M51-GFP at MOI 10 (based on 4T-1) for 16 
h, further reduced MxA and OAS protein to below detectable levels in uninfected cells 
and sharply reduced them in infected cells (Figure 13).  In general, MxA and OAS 
expression in mock treated cells was consistent with that seen in Figure 12, despite 
different treatment conditions, although some variation was noted (e.g., MxA levels in 
HPAC cells). 
When new infectious virus particle production was determined following JAK Inh 
I treatment, by collecting supernatants and titering them on BHK-21, increases were seen 
for the resistant cell lines (CFPAC, HPAC, HPAF-II, HPDE and Hs766t) (Table 6).  
Consistent with the improvement in virus production, a robust increase in viral protein 
accumulation was seen for the resistant cell lines CFPAC, HPAC, HPDE and Hs766T 
and a slight increase was seen for the resistant cell line HPAF-II.  Treatment also caused 
a modest increase in viral protein accumulation in Suit2, a cell line we classify as 
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susceptible.   While titers were well correlated with viral protein as determined by 
western blot, this was not absolute, possibly due to low viral titers in some cell lines 
(especially HPAF-II) and cell line variations in virus replication kinetics and 
infectious/non-infectious particle ratios.   
Our previous study showed a correlation between susceptibility of PDA cells to 
VSV-mediated cell death and the relative infectivity of VSV on different PDA cell lines 
(Murphy, Besmer et al. 2012). To determine if inhibition of JAK/STAT signaling 
improved VSV-∆M51-GFP infectivity in resistant cells, VSV-∆M51-GFP was titered on 
mock treated cells or cells treated with JAK Inh I for 48 h.  Consistent with previous 
results (Murphy, Besmer et al. 2012), titers were lower on resistant cell lines (CFPAC, 
HPAC, HPAF-II, HPDE, Hs766T) than susceptible cell lines (AsPC-1, MIA PaCa-2, 
Suit2). This difference remained even with JAK Inh I treatment.  However, some 
improvement in titer was observed on HPAC and HPAF-II with treatment (Figure 14), 
although it was statistically significant only for HPAF-II.  We observed for all resistant 
cell lines, with the possible exception of HPDE, a clear increase in plaque size upon JAK 
Inh I treatment.  An increase in plaque size was also observed on the susceptible AsPC-1 
cell line at the highest inhibitor concentration.  This data suggests that while activation of 
the JAK/STAT pathways contributes to resistance to VSV-∆M51-GFP in most resistant 
cell lines, other factors may contribute to the differences in VSV titers in various PDA 
cell lines. 
To determine if the improvement in new infectious particle production and plaque 
size translated into improved cell killing, cells were pretreated with JAK Inh I for 48 h 
and infected with VSV-∆M51-GFP at MOI 1 (based on 4T-1).  Virus-directed GFP 
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expression was measured every 24 h and cell viability was determined at the end of five 
days by MTT assay.  GFP expression increased upon JAK Inh I treatment for all five 
resistant cell lines plus the susceptible cell lines AsPC-1 and Suit2 (Figure 15).  No 
increase was seen for the susceptible cell line MIA PaCa-2.  When cell viability was 
determined (Figure 16A), a statistically significant increase in VSV-mediated cell death 
was seen with inhibitor treatment for HPDE, the expected outcome for a “normal’ (non-
malignant) cell line. Importantly, a similar result was observed in the VSV-resistant 
CFPAC-1, HPAC and Hs766T cell lines at least at the highest concentration of inhibitor 
(2.5µM), suggesting an involvement of JAK/STAT signaling in the resistance phenotype 
of these cell lines. Treatment with JAK Inh. I alone generally did not cause a loss in cell 
viability, as measured by MTT, although a statistically significant decrease was seen for 
Hs766T at the lowest concentration only, HPDE at the highest concentration only and 
Suit2 at both concentrations. Consistent with the possible cytotoxic effects of JAK Inh I 
on Suit2 and HPDE, virus-directed expression of GFP dropped at the higher 
concentration (2.5 µM) compared to the lower concentration (0.5 µM), although it still 
exceeded expression in untreated cells (Figure 15). Interestingly, in some cases, most 
notably HPAF-II, JAK Inh I caused a significant increase in MTT signal in uninfected 
cells.  This may be due to an increase in the number of viable cells or due to an increase 
in mitochondrial activity (the actual parameter measured by the MTT assay), which can 
be caused by stress.  To more specifically look at this question, the experiment was 
repeated with HPAF-II with a parallel plate used for cell counting.  While less dramatic 
than in the previous experiment, treatment with 2.5µM JAK Inh I alone did cause a 
statistically significant increase in MTT signal (Figure 16B).  However, this treatment did 
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not change the number of viable cells number (Figure 16B).   This experiment also 
confirmed that treatment of HPAF-II with 2.5 µM JAK Inh. I caused an increase in cell 
killing by VSV-∆M51-GFP.    
Susceptibility of PDA cells to other viruses. 
The ability of VSV-∆M51-GFP to initiate infection on the PDA and HPDE cell lines was 
assessed by performing a plaque assay using serial dilutions of virus Permissiveness was 
expressed as a ratio of the viral titer on PDA cell line to the titer on Vero cells with 
higher numbers indicating greater permissiveness and cell lines listed in order of 
permissiveness (Figure 17). In confirmation of our previous results, the five resistant cell 
lines (CFPAC, HPAC, HPAF-II, HPDE and Hs766T) showed the least susceptibility to 
VSV-∆M51-GFP, in terms of both plaque size and number, and formed a distinct cluster 
from the susceptible cell lines.  All of these highly resistant cells constitutively express at 
least some ISGs, including MxA and OAS, not seen in the more susceptible cell lines.  In 
contrast, the two PDA cell lines where VSV-∆M51-GFP formed the largest plaques 
(MIA PaCa-2 and Capan-1) are the only cell lines that fail to express both IFN-α and β 
following VSV-∆M51-GFP infection (Figure 11 and 12).  Previous studies showed that 
VSV is highly sensitive to type I IFN responses, an effect even more pronounced in 
VSV-∆M51-GFP as a result of the methionine 51 deletion in the M protein (Coulon, 
Deutsch et al. 1990; Black, Rhodes et al. 1993; Stojdl DF 2003). If indeed the 
susceptibility profile of these cells is at least in part determined by their type I IFN status, 
it would be expected that viruses capable of evading the host type I IFN response would 
display a different profile.  To test this hypothesis, we used two large DNA viruses 
unrelated to VSV, recombinant vaccinia virus VVT7 (a poxvirus) and HSV-1 (a 
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herpesvirus), both of which have been shown to evade type I IFN antiviral responses 
(Paladino and Mossman 2009; Perdiguero and Esteban 2009).  While the specific VV and 
HSV-1 viruses used in this experiment are not used as OVs, other recombinants based on 
VV and HSV have been developed for that purpose.  When VVT7 and HSV-1 were 
titered on PDA cell lines, there was not a correlation between the permissiveness of cells 
to these two viruses (Figure 17) and their type I IFN status (Figure 11 and 12), as 
indicated by the different ordering of these cells lines by permissiveness as compared to 
VSV-∆M51-GFP.  This is consistent with the greater abilities of VVT7 and HSV-1 to 
evade this pathway.  The degree of curvature of the graphs in Figure 17 indicates the 
variability in cell line permissiveness to the viruses.    The variability in cell line 
permissiveness was similar for VSV-∆M51-GFP and HSV-1 although they differed in 
which cell lines were susceptible or resistant.  In contrast, the range much smaller for 
VVT7 with the exception of highly resistant (to VVT7) Capan-2 
To determine if susceptibility of the PDA cells to these three viruses extended to 
cell killing, cell viability was determined by MTT assay at 5 d p.i. following infection 
with VSV-∆M51-GFP, VVT7 or HSV-1 at MOI 1 or 0.01 as determined by titration on 
Vero cells that support robust replication of all three viruses (Fig. 18).  For VSV-∆M51-
GFP, results closely mimicked those reported in our previous study (Murphy, Besmer et 
al. 2012). However, all VSV-resistant cell lines (CFPAC-1, HPAC, Hs766T, HPAF-II 
and HPDE), were more effectively killed by HSV-1 and VVT7 than VSV-∆M51-GFP at 
MOI 1, and this was also true for most of those cell lines at MOI 0.01.  Importantly, 
HSV-1 and VVT7 did not demonstrate superior oncolytic abilities in all cell lines (eg. 
AsPC-1 and Capan-2 at MOI 0.01).  Although we cannot rule out that other (IFN-
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unrelated) factors influenced cell susceptibility to these three viruses, the results are 
consistent with type I IFN responses being at least a factor in determining resistance to 





   
 
3.5 Discussion 
In this study, we demonstrated on a molecular level that the resistant cell lines 
tested have functional type I IFN responses similar to those observed in the non-
malignant HPDE cell line. Importantly, we found that, unlike susceptible PDA cells, 
resistant cell lines constitutively expressed high levels of MxA and OAS, two important 
IFN-stimulated antiviral proteins.  
We previously showed that while the majority of tested PDA cell lines were 
highly susceptible to VSV-∆M51-GFP, five of these cell lines (BxPC-3, CFPAC-1, 
HPAC, HPAF-II and Hs766T) and the non-malignant pancreatic duct epithelial cell line 
HPDE were at least somewhat resistant to VSV-∆M51-GFP mediated oncolysis 
(Murphy, Besmer et al. 2012). The same pattern of resistance was also observed for wt 
VSV and VSV-p1-GFP, with a minor deviation for wt VSV in that HPDE and CFPAC 
were more susceptible than AsPC-1 and T3M4 (Murphy, Besmer et al. 2012). These 
phenotypes were confirmed here for VSV-∆M51-GFP (Fig. 17 and 18). However, it 
should be noted that BxPC-3, previously shown to be highly resistant to VSV (Murphy, 
Besmer et al. 2012), was omitted from this study as it displayed an unstable phenotype, 
being generally resistant but occasionally highly susceptible to VSV-∆M51-GFP.  Even 
though passage numbers were limited for all tested cell lines, we observed that increased 
passage number tended to correlate with increased susceptibility of BxPC-3 to VSV-
∆M51-GFP suggesting alterations in cell biology may be responsible for this variability. 
BxPC-3 cells in culture have been shown to undergo an epithelial to mesenchymal 
transition (Roy, Sahraei et al. 2011). Interestingly, our previous study showed BxPC-3 
differed from the other highly resistant cell lines in that secretion of IFN-β was not 
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detectable following VSV infection (Murphy, Besmer et al. 2012). Further studies are 
needed to better understand the BxPC-3 phenotype.       
In order to mount an effective IFN mediated antiviral response, cells must first 
detect the virus.  For RNA viruses replicating in the cytoplasm, such as VSV, detection 
occurs primarily through binding of single or double stranded viral RNA to RIG-I or 
melanoma differentiation associated gene 5 (MDA5) (Nakhaei, Genin et al. 2009; 
Shmulevitz, Pan et al. 2010).  This initiates a signaling cascade resulting in 
phosphorylation of IRF 3 and 7 and formation of homo- and heterodimeric transcription 
factors necessary for expression of the type I IFNs α and β. Both of these secreted IFNs 
bind to the IFNAR1/2 receptor of the infected as well as surrounding non-infected cells, 
resulting in phosphorylation of the receptor by the Janus kinases JAK1 and TYK2.  This 
results in recruitment and phosphorylation of STAT1 and STAT2 which together with 
IRF9 form a transcription factor, ISGF3, which recognizes IFN-stimulated response 
elements (ISRE) leading to transcription of ISGs, many of which have direct antiviral 
functions or contribute to the formation of an antiviral state. Several of these ISGs, 
including ISG15, MxA, OAS and PKR, have been shown to effectively inhibit replication 
of rhabdoviruses such as VSV (Sadler and Williams 2008).  
The high sensitivity of VSV to type I IFN responses is a major factor determining 
VSV’s oncoselectivity, as it is believed most cancer cells are defective in type I IFN 
responses (Stojdl, Lichty et al. 2000; Naik and Russell 2009). However, some cancers 
retain the ability to produce and/or respond to type I IFN (Stojdl, Lichty et al. 2000; Naik 
and Russell 2009). For example, PC3 prostate cancer cells (Ahmed M, Cramer SD et al. 
2004; Carey, Ahmed et al. 2008), SW982 human sarcoma cells (Paglino and van den Pol 
93 
   
2011), RT-4 and RT112 bladder cancer cells (Zhang, Matsui et al. 2010), and multiple 
mesothelioma cells lines (Saloura, Wang et al. 2010) have been shown to be resistant to 
VSV infection at least in part due to IFN responsiveness and/or constitutive ISG 
expression.  Furthermore, constitutive ISG expression was shown to be predictive of 
permissiveness of several PDA cell lines to adenovirus infection (Monsurro, Beghelli et 
al. 2010). Given this and our previous data demonstrating many resistant PDA cell lines 
both produce and respond to type I IFN (Murphy, Besmer et al. 2012), as does the 
“normal” non-malignant HPDE cell line, we examined the responses of these cell lines to 
VSV-∆M51-GFP at the molecular level. All tested cell lines appeared to be able to sense 
VSV-∆M51-GFP as seen by production of IFN-λ mRNA and an increase in IRF3 
phosphorylation following infection, even in cell lines where IFN-α and/or β transcription 
is not induced (Fig. 11 and 12).  
STAT1 phosphorylation was detected in response to VSV-∆M51-GFP infection 
in the resistant cell lines and in the susceptible cell lines AsPC-1 and Suit2, although the 
response in Suit2 was not robust. In the susceptible Mia PaCa-2 cells, STAT1 was 
phosphorylated in response to exogenously added IFN-α but not to VSV-∆M51-GFP, 
suggesting the inability of this cell line to produce type I IFN (possibly due to poor IRF7 
expression).  
Importantly, MxA was constitutively expressed at both the mRNA and protein 
level in all resistant cell lines but in none of the susceptible cell lines.  MxA has broad 
antiviral activity against a wide range of RNA and even some DNA viruses, regardless of 
subcellular site of replication (Haller and Kochs 2011). It is believed that MxA GTPases 
recognize viral RNP complexes and form oligomeric rings around them, thereby blocking 
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their function. MxA has also been implicated in the hyperphosphorylation of VSV P 
protein, which may interfere with its function (Schuster, Johnston et al. 1996/6/1). 
Constitutive expression of MxA (270-fold over baseline) was observed in SW982 
sarcoma cell line resistant to VSV (Paglino and van den Pol 2011). Similarly, increased 
expression of MxA in PDA cells was recently associated with resistance to adenovirus-
based OV (Monsurro, Beghelli et al. 2010). Furthermore, OAS was constitutively 
expressed in all the resistant cell lines as well as a few susceptible cell lines, at least at the 
mRNA level, although the highest levels were detected in resistant cell lines. OAS 
converts adenosine triphosphate into a series of 20-50 oligoadenylates (2-5A), which 
activate the latent ribonuclease (RNaseL). The activated OAS-RNaseL system promotes 
apoptosis, attenuates proliferation, degrades viral and cellular RNA, and inhibits protein 
synthesis (Justesen, Hartmann et al. 2000; Mandal, Abebe et al. 2011). Previous studies 
showed increased expression of OAS in PDA cells resistant to adenoviruses (Monsurro, 
Beghelli et al. 2010), and human mesothelioma cells resistant to VSV (Saloura, Wang et 
al. 2010).  As both MxA and OAS have been shown to have antiviral activity against 
VSV, they almost certainly contribute to the resistance phenotype of the PDA cells 
studied here.  However, as there are hundreds of ISGs, a number of which also have 
known antiviral functions (Sadler and Williams, 2008), resistance is likely to involve 
more than just these two proteins. 
It is unclear why these proteins are expressed constitutively at high levels. While 
low levels of phosphorylated STAT1 were detected in some uninfected resistant cell 
lines, it is uncertain whether these levels were sufficient for the observed expression of 
MxA and other ISGs in uninfected cells. However, the strong reduction in MxA and OAS 
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protein levels upon inhibition of JAK/STAT signaling (Fig. 13) would argue the effect is 
at least partially mediated through this mechanism.  It is also not clear why not all 
resistant cell lines constitutively express all of the ISGs tested, since the ISGs are all 
under the control of ISREs. One possibility is that alternative regulatory mechanisms 
influence expression of some of these genes.  For example, RelA (p65 subunit of NF-κB) 
has been shown to regulate a subset of ISGs (Basagoudanavar, Thapa et al. 2011). IFN-λ 
is also known to regulate ISG expression, although it regulates those genes through the 
same mechanisms as type I IFN and the resulting ISG expression profile is thought to be 
nearly identical (Donnelly and Kotenko 2010). Expression of these genes may also be 
influenced by chromosome modification as treatment with a histone deacetylase inhibitor 
was shown to decrease ISG expression and increase VSV infectivity in the SW982 
human sarcoma cell line (Paglino and van den Pol 2011). Since the NF-κB signaling 
regulates several pathways and has been implicated to be involved in carcinogenesis the 
possible role of its activation in ISG induction is further investigated, however not 
discussed in this dissertation. 
In our study, five of the 11 human PDA cell lines tested showed constitutive 
expression of the ISGs MxA and OAS.  While this collection of cell lines is likely not 
representative of the clinical situation, a recent study showed that a significant subset of 
the bulk PDA tissues and xenografted primary PDA cells tested had an mRNA 
expression profile typical of an inflamed state including upregulation of ISGs such as 
MxA (Monsurro, Beghelli et al. 2010), demonstrating the existence of this phenotype in 
the patient population.  In addition, we have identified a number of cell lines able to 
respond to type I IFN (Murphy, Besmer et al.) as well as produce type I IFN in response 
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to VSV-∆M51-GFP.  While all of these cell lines were susceptible to VSV-∆M51-GFP in 
vitro, results presented here suggest that the type I IFN responsiveness of these cells may 
lead to suboptimal VSV-∆M51-GFP oncolysis.  For example, virus-directed GFP 
expression increased in both AsPC-1 and Suit2 upon JAK Inh. I treatment (Figure 15) 
and AsPC-1 plaque size increased when the higher concentration of inhibitor was used. 
Given these phenotypes, our results suggest that high constitutive expression of 
ISGs may be useful biomarkers in identifying PDAs, and possibly other cancers, resistant 
to OV therapy with VSV or other viruses highly sensitive to IFN.  In our study, the ISGs 
MxA and OAS were particularly well correlated with this phenotype.  While PDAs with 
this profiles are unlikely to be successfully treated with IFN sensitive OVs such as VSV, 
use of alternative OVs (e.g. vaccinia virus or HSV-1), better equipped to evade IFN 
responses could be a better option. Alternatively, treatment with more than one OV 
(combined virotherapy) could also lead to enhanced oncolysis as was previously shown 
for VSV in combination with vaccinia virus (Le Boeuf, Diallo et al. 2010).  Furthermore, 
any future OV therapy will likely involve a combination of OV(s) and chemotherapy 
(Ottolino-Perry, Diallo et al. 2010).  
While we have demonstrated a role for type I IFN responses in the resistance of 
PDA cells to VSV-∆M51-GFP infection, we cannot rule out the possible influence of 
other factors on susceptibility and/or oncolysis.  For example, VSV has been shown to 
cause cell death via apoptosis (Gaddy DF and and Lyles 2005; Gaddy DF and and Lyles 
2007; Sharif-Askari, Nakhaei et al. 2007; Cary, Willingham et al. 2011), and inhibition of 
apoptosis, a signature of many cancer cells (Hamacher, Schmid et al. 2008), has the 
potential of limiting/delaying cell death following VSV infection. Studies are in progress 
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examining the role apoptosis and other factors may have in contributing to the resistance 
















Figure 11. mRNA expression of IFN related genes.  Cells were mock infected (-) or 
infected (+) with VSV-∆M51-GFP at MOI 10 CIU/cell and harvested at 4 h p.i. Extracted 
mRNA was reverse transcribed and then analyzed by semi-quantitative PCR for the 
indicated genes. PCR product sizes are indicated on the right. 
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Figure 12.  mRNA and protein expression of IFN related genes.  Cells were mock 
infected, infected with VSV-∆M51-GFP (indicated as VSV) at MOI 10 CIU/cell or 
treated with 5,000 U/ml IFN-α.  Cells were harvested at 12 h p.i. and mRNA was reverse 
transcribed and analyzed by semi-quantitative PCR or cell lysates were prepared and 
analyzed by western blot for the indicated protein.  PCR (nt) and protein (kDa) product 
sizes are indicated on the right. 
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Figure 13.  Effect of JAK/STAT signaling inhibition on p-STAT1, MxA and OAS 
expression.  Cells were mock (DMSO) treated or treated with 0.5 or 2.5µM JAK Inh I for 
48 h prior to infection with VSV-∆M51-GFP at MOI 10 CIU/cell.  Cells were harvested 
at 16h p.i. and cell lysates were prepared and analyzed by western blot for the indicated 
proteins. *, position of M protein in JAK Inh I treated HPAF-II cells  
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Figure 14.  Effect of JAK/STAT signaling inhibition on PDA cell susceptibility to VSV-
∆M51-GFP. Cells were mock (DMSO) treated or treated with 0.5 or 2.5µM JAK Inh I for 
48 h prior to infection with serial dilutions of VSV-∆M51-GFP.  At 17hpi, VSV-∆M51-
GFP fluorescent foci were counted to determine viral titers. Titers are expressed as a ratio 
to the mock treated titer, with the mock treated titer indicated.  Titers were done in 
duplicate and data represent the mean ± standard error of mean. Treatments were 
compared using a 1-way ANOVA followed by the Bonferroni posttest for multiple 













   
3.6 Figures continued 
 
 
Figure 15.  Effect of JAK/STAT signaling inhibition on virus-directed GFP expression. 
Cells were mock (DMSO) treated or treated with 0.5 or 2.5µM JAK Inh. I for 48 h prior 
to infection with VSV-∆M51-GFP at MOI 1 CIU/cell.  GFP fluorescence following 










   
3.6 Figures continued 
 
Figure 16.  Effect of JAK/STAT signaling inhibition on PDA cell viability following 
infection.  (A) Cells were mock (DMSO) treated or treated with 0.5 or 2.5µM JAK Inh. I 
for 48 h prior to infection with VSV-∆M51-GFP at MOI 1 CIU/cell. Cell viability was 
analyzed by MTT assay at 5 d p.i. and is expressed as a percent of the DMSO only 
(mock) control.  (B) The same assay was also performed in parallel with viable cell 
counts.  The assays were done in triplicate and data represent the mean ± standard error 
of mean.  Treatments were compared using a 1-way ANOVA followed by the Bonferroni 
posttest for multiple comparisons. Within each cell line, the presence of the same letter 
above a bar indicates treatments are not statistically different (cut-off p<0.05).  For 
example, a bar marked “ab” does not differ from one marked “a” or “b” but is 






   
 





Figure 17.  Permissiveness 
of PDA cell lines to VSV-
∆M51-GFP, VVT7 and 
HSV-1. Cells were infected 
with serial dilutions of virus 
and, after a 1 h absorption, 
overlayed with media 
containing 0.5% BactoAgar.  
VSV-∆M51-GFP foci were 
counted by fluorescent 
microscopy at 3 d p.i.  VVT7 
and HSV-1 plaques were 
counted after staining with 
crystal violet at 5 d p.i.  
Titers are expressed relative 
to those on Vero cells.  A 
relative yield of 0 indicates 
that the PDA cell line and 
Vero are equally permissive 
to the virus, while negative 
numbers indicate reduced 
permissiveness on the PDA 
cell line. Plaque size was 
determined for all viruses at 




   
 
3.6 Figures continued 
 
 
Figure 18. PDA cell viability following infection with VSV-∆M51-GFP, VVT7 and 
HSV-1. Cells were mock infected or infected with VSV-∆M51-GFP, VVT7 or HSV-1 at 
MOI of 1 (A) or 0.01 (B) CIU/cell. Cell viability was analyzed by an MTT assay at 5 d 
p.i. and expressed as a percent of mock-infected controls. MTT assays were done in 












Table 4. Human pancreatic cell lines used in this study and a summary of VSV-ΔM51-
GFP susceptibility and expression of select mRNAs. 
 
a 
All cell lines (except for non-malignant HPDE) have PDA origin 
b
LN, lymph node 
c
 -, susceptible; +, intermediate; ++, resistant; +++ highly resistant 
d
 mRNA expression undetectable or barely detectable 
e
 mRNA robustly expressed 
f











   
 
 
3.7 Tables continued 
 
 
Table 5. Summary of VSV-ΔM51-GFP susceptibility and expression of selected proteins.
 
a
 -, susceptible; +, intermediate; ++, resistant; +++ highly resistant 
b
 protein expression undetectable or barely detectable 
c
 protein robustly expressed 
d
 protein expression increases upon VSV-ΔM51-GFP infection 
e




























3.7 Tables continued  
 
 
Table 6. New infectious virus particle production at 16 h p.i. after 48 h pre-treatment with 
JAK Inh I. 
 
a
 “VSV” indicates VSV-∆M51-GFP 
b 
Virus was collected from the indicated cell line and titer was determined on BHK-21 
cells 
c




   
3.7 Tables continued 
 
Table 7. List of target genes and oligonucleotides used in the study.  
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3.7 Tables continued  
 
 




   
3.7 Tables continued 
 
 
Table 7 continued. List of target genes and oligonucleotides used in the study. 
a 
(+) indicates primer has mRNA polarity, (-) indicates primer is complimentary to 
mRNA.  
b 
Except for MAVS, Myd88, NF- κB, IKBKE, SOCS1 and RIG-I,  at least one primer in 
each pair was selected to span an exon-intron boundary 
CHAPTER 4: DISSERTATION SUMMARY AND CONCLUSION 
 
In Summary, my first study demonstrated that certain cell types are naturally 
resistant to ribavirin treatment without any prior exposure to the drug. Our data also 
indicated that differences in the intracellular RBV metabolism among cell types may be 
responsible for the natural resistance. Further experiments are required to identify 
specific cellular factors responsible for defective ribavirin metabolism in ribavirin 
resistant cell types. These results may explain some treatment failures with ribavirin 
therapy. Targeting these factors may improve the therapeutic outcome of ribavirin 
therapy in virus-infected patients.  
In the second study, specific genes involved in type I IFN signaling are evaluated 
for their role in resistance of specific PDA cells to oncolytic VSV-ΔM51-GFP. We 
demonstrated that ISGs such as MxA and OAS may be useful biomarkers to identify 
PDAs susceptible for VSV-ΔM51-GFP mediated oncolysis. Further research can lead to 
a better understanding of resistance, which can help us to design newer drugs to target 









   
 
4.1 Ribavirin resistance 
Ribavirin was chemically synthesized more than 40 years ago and approved to use 
in humans against respiratory syncytial virus (RSV) 20 years ago. Later it is also 
approved against Lassa fever virus infection and in combination with IFN-α against HCV 
infections. Moreover, ribavirin has been shown to be effective in preclinical models 
against various RNA and DNA viruses. Despite of these successes, some patients exhibit 
resistance to ribavirin treatment and the exact mechanism of this resistance is not fully 
understood (Liuzzi, Mason et al. 2005; Ibarra and Pfeiffer 2009). For example, ribavirin 
treatment in combination with IFN fails to induce sustained virological response (SVR) 
in ~45% patients with chronic HCV infection (Liu, Su et al. 2007; Thomas, Feld et al. 
2010). Moreover, ribavirin has very limited success when used against respiratory 
syncytial virus (RSV) infection in children and Lassa fever virus infection. Importantly, 
increased concentration of ribavirin within the cell is linked to increased antiviral 
response (Feld and Hoofnagle 2005). Since majority of previous studies focused on the 
generation of ribavirin resistant virus mutant, we wanted to study the host based 
resistance of ribavirin using cell culture system. Even though longer exposure to ribavirin 
treatment may result in the development of drug resistance (Ibarra and Pfeiffer 2009), we 
aim to identify cell types which can be naturally resistant to ribavirin treatment and 
factors responsible for such resistance. 
Several studies have shown that ribavirin resistant mutant viruses can be 
developed with long term exposure of ribavirin treatment (Airaksinen, Pariente et al. 
2003; Pfeiffer and Kirkegaard 2003; Vignuzzi, Stone et al. 2005; Sierra, Airaksinen et al. 
2007; Cuevas, Gonzalez-Candelas et al. 2009). However, this has not been established 
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with VSV (Cuevas, Sanjuan et al. 2005). In addition, ribavirin resistant cells infected 
with VSV or SeV exhibited no signs of virus adaptation. When VSV was passed for 15 
passages in HeLa, BSRT7 or in BHK cells in the presence of inhibitory ribavirin 
concentrations no increase in viral titer or infectivity was observed to suggest any 
possibility of virus adaptation. A previous study could not find a ribavirin resistant VSV 
mutant even after 100 generations in the presence of sub-inhibitory concentrations of 
ribavirin (Cuevas, Sanjuan et al. 2005). 
In this study we analyzed the antiviral activity of ribavirin in the panel of seven 
different cell types from various hosts against VSV and SeV. Though, both viruses 
belong to the same order, they belong to two different families having different 
morphology and replication kinetics. Previously it has been shown that replication of 
both of these viruses can be effectively inhibited by ribavirin treatment both in vitro and 
in vivo (Sidwell, Khare et al. 1975; Larson, Stephen et al. 1976; Toltzis and Huang 
1986/6; Toltzis, O'Connell et al. 1988/4). Also, ribavirin has been shown to be very 
effective against various viruses of order Mononegavirales (Wray, Gilbert et al. 1985; 
Leyssen, Balzarini et al. 2005; Sun, Chung et al. 2007) (Malinoski and Stollar 1980; 
Smee, Bray et al. 2001). However, all these studies utilized only one or two cell lines to 
test the efficacy of ribavirin against a particular virus. We tested the inhibitory effect of 
ribavirin on seven different cell types against two different viruses. Our results 
demonstrated that specific cell types such as Vero (IC50=2250 µM for VSV and 1550 µM 
for SeV) were highly resistant to ribavirin whereas, A549 and BHK cells showed 
moderate resistance to ribavirin treatment. The other tested cell types including HeLa, 
HEp2, 4T1 and BSRT7 inhibited both VSV and SeV at much lower ribavirin 
115 
   
concentration than resistance cells. The observed ribavirin resistance was irrespective of 
virus or host type. We hypothesized that resistance of RBV against VSV and SeV is 
mainly attributed to cellular factors and not viral factors and RBV metabolism might play 
a key role for this observed resistance. We demonstrated that both VSV and SeV 
replication kinetics over the period of 24 h and 48 h are very different and the conferred 
resistance of RBV is not due to the toxicity of ribavirin. 
A recent study showed that cell-based ribavirin resistance can be developed after 
continuous exposure with ribavirin and it’s mainly because of limited uptake through 
nucleoside transporters (Ibarra and Pfeiffer 2009). When we tested all of our seven cell 
lines for the ribavirin uptake, we observed that none of our tested cell lines were 
defective in ribavirin uptake. We also used NBMPR a specific inhibitor of equilibrative 
nucleoside transporter (ENT) and demonstrated that ENT1 or ENT2 are mainly 
responsible for ribavirin uptake. However, when we compared the accumulation of 
ribavirin after 24 h post treatment, we found clear correlation between the ribavirin 
resistance and low levels of ribavirin accumulation. In other words, cells most sensitive 
to ribavirin treatment (HeLa, HEp2, BSRT7 and 4T1) had the highest levels of 
intracellular ribavirin and vice versa. As mentioned earlier in chapter two, it is known 
that intracellular uptake of ribavirin results in the phosphorylation of ribavirin and once 
phosphorylated, ribavirin is trapped inside the cell (Endres, Moss et al. 2009).  Thus it 
can be assumed that ribavirin resistant cells in some capacity are defective in ribavirin 
metabolism and this defect is at least partially responsible for the resistance.  
The mechanism of action of ribavirin is still highly controversial mainly due to its 
pleiotropic nature. One of the most common mechanisms of action of ribavirin is via 
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inhibition of IMPDH which results into the depletion of cellular GTP pool. This reduced 
GTP levels negatively affects viral replication. However, the GTP levels can be restored 
if the cells are co-treated with exogenous guanosine. We did not observe any drastic 
reversal in the activity of RBV in any of the VSV or SeV infected ribavirin sensitive cell 
types (HeLa, HEp2, BSRT7 or 4T1). In few previous studies a general inhibitor of 
transcription ActD has been shown to reverse the antiviral action of ribavirin either by 
stabilization of GTP levels or by inhibition of RTP synthesis (Malinoski and Stollar 
1980; Smee and Matthews 1986). Our results demonstrated that ActD but not guanosine 
reversed the antiviral effect of ribavirin. These results led us to further hypothesize that 
effect of ribavirin is dependent on the synthesis of ribavirin mono-, di- or tri- phosphates 
(RMP/RDP/RTP).  In addition, recently it has been shown that ribavirin treatment-
induced specific interferon stimulated genes (ISG), may be important for the inhibition of 
viral replication (Feld and Hoofnagle 2005; Thomas, Feld et al. 2010). Since ActD 
inhibits the general cellular transcription, it can be hypothesized that ActD neutralizes the 
effect of ribavirin by inhibiting the transcription of specific ISGs, which are required for 
its activity.  
Together, our data suggested that IMPDH inhibition is not the primary 
mechanism of action against VSV and SeV at least in the cell types tested and other 
mechanisms (explained above) alone or together might contribute for the antiviral 
activity of ribavirin.  
 Very similar pattern of ribavirin activity was observed against both VSV and 
SeV, suggests that it is possible that both viruses are being inhibited by the same 
mechanism even though they belong to different families. Previously, mechanism of 
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ribavirin’s antiviral action has not been studied for SeV. However, for another 
paramyxovirus RSV, IMPDH inhibition and depletion of GTP levels has been shown as 
the primary mechanism of action of ribavirin (Leyssen, Balzarini et al. 2005). In contrast, 
in a previous study utilizing in vitro transcription reaction with purified VSV indicated 
that RMP, RDP and RTP significantly inhibited VSV RNA polymerase activity and RNA 
synthesis (Toltzis and Huang 1986/6). To better understand the molecular mechanisms of 
the antiviral activity of ribavirin against VSV and SeV, we plan to investigate the 
metabolism of ribavirin in ribavirin resistant and sensitive cell types. This will help us to 
identify, cellular factors responsible for defective ribavirin metabolism. In order to 
understand the molecular mechanism of action of ribavirin, we plan to investigate the 
expression profile of ribavirin resistant and sensitive cell types when treated with 
ribavirin. This experiment is important, since ribavirin treatment has been suggested to 
modulate the expression of specific ISGs and this expression profile may contribute to 
the antiviral activity of ribavirin. We plan to isolate total RNA and determine the mRNA 
expression of several genes regulated by ribavirin treatment using Affymatrix microarray. 
Overall, our study provided the first evidence that some cells can be naturally 
resistant to ribavirin. Our results may explain some of these failures associated with the 
treatment of ribavirin. In future, experiments can be aimed to study efficacy of ribavirin-
IFN combined treatment in several cell types against various viruses. These studies could 
identify the specific cellular factors responsible for such resistance. Once these cellular 
targets are found, several ribavirin-like compounds, which are better to overcome cell 
based resistance can be synthesized and tested for improved efficacy. Furthermore, the 
most efficacious compounds can be tested in vivo to study their pharmacokinetics and 
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dosage. Moreover, liver tissue samples from patients with chronic HCV infection can be 

























   
4.2 New approaches to overcome oncolytic VSV resistance in cancer cells 
Previous study from our laboratory analyzed for the first time VSV as an 
oncolytic agent against PDA and observed great heterogeneity among different cell lines 
in the susceptibility to VSV. Out of 13 tested PDA cell lines, five cell lines (BxPC-3, 
CFPAC-1, HPAC, HPAF-II and Hs766t) and a non-malignant HPDE cells were at least 
partially resistant to VSV-ΔM51-GFP (Murphy, Besmer et al. 2012). This study also 
revealed that all the VSV resistant cell types both secreted and responded to Type I IFN. 
Type I IFN includes IFN-α and IFN-β. Both IFN-α/β, provide an essential host defense 
against various viruses by triggering the innate antiviral responses in cells. Once 
synthesized IFNs are secreted and can work in autocrine or paracrine manner to exert its 
antiviral activity. All the members of the type I IFN family can be recognized by a single 
receptor known as IFNAR. This receptor is attached with Janus kinases Jak1 and Tyk2. 
Jak1 and Tyk2 activate STAT1 and STAT2 upon binding of type I IFN onto IFNAR. 
Transcription factors STAT1 and STAT2 subsequently get dimerized to form a complex 
with IRF9. This complex is known as ISGF3 and binds to ISRE site on DNA and leads to 
the activation of hundreds of genes. Many of these genes are interferon stimulated genes 
(ISGs) and known to have direct antiviral activity against various viruses including VSV.  
The basis of VSV oncoselectivity is based on the fact that majority of cancer cells 
are defective in Type I IFN responses (Stojdl, Lichty et al. 2000; Naik and Russell 2009). 
However, some cancer cells have been found to have intact type I IFN response (Carey, 
Ahmed et al. 2008; Paglino and van den Pol 2011). A few recent studies have indicated 
that constitutive expression of specific ISGs can predict the susceptibility to OV 
(Monsurro, Beghelli et al. 2010).  
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Based on our previous data and recent publications we hypothesized that the 
constitutive expression of specific ISGs in specific PDA cells might contribute to the 
VSV-ΔM51-GFP resistance. To test this hypothesis we examined 12 PDA cells and one 
non-malignant HPDE cell line at molecular levels for several genes involved in type I 
IFN responses. Our data showed that MxA was expressed constitutively at both RNA and 
protein level in all VSV resistant cell lines but not in any of the sensitive cell lines. MxA 
is an interferon-induced dynamin like GTPases. MxA exhibited antiviral activity against 
a variety of RNA viruses by blocking the transport of viral nucleocapsids into the nucleus 
and thereby preventing transcription of the viral genome. In addition, OAS was also 
found to be constitutively expressed in all resistant cell types and in few susceptible cell 
types at least at mRNA level. We also observed the low levels of pSTAT1 in some of the 
resistant cell types. Also, susceptibility to VSV increases in all resistant cells, when MxA 
and OAS expression is reduced by the inhibitor of Jak/STAT signaling. Together, this 
data suggest at least partial role of pSTAT1 in constitutive expression of ISGs.  
Here we showed that expression of MxA and OAS can be used as a biomarker of 
resistance against PDA cells for the treatment with oncolytic VSV. In this study we 
utilized the general inhibitor of type I IFN signaling to downregulate the expression of 
MxA and OAS. However, this inhibitor may exhibit its inhibitory effect against other 
ISGs. To further demonstrate that, this resistance is mainly due to the constitutive 
expression of MxA and OAS, we are going to use the specific sh-RNA targeting MxA 
and OAS mRNAs. If the treatment with specific sh-RNA against MxA and OAS results 
in increased virus replication and cell death in resistant PDA cells, that will further 
confirm the major role of these two proteins in PDA resistance. 
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In this study we clearly demonstrated the role of type I IFN responses in the 
resistance of PDA cells to VSV-ΔM51-GFP. However, it is possible that other 
mechanisms are involved with these resistance phenotypes. For example NF-κB 
activation has been implicated to regulate the transcription of IRF3/7 (Hiscott, Grandvaux 
et al. 2003). These findings indicate that it is possible that up-regulation of specific ISGs 
such as MxA and OAS is NF-κB driven. Also, defects in cellular apoptotic pathway has 
been shown to acquire resistance to oncolytic VSV in glioblastoma cells(Gaddy DF and 
and Lyles 2007). 
For future, two independent projects are in progress to evaluate the possible 
involvement of these other mechanisms with VSV resistant phenotype of PDA cells. The 
first project is to analyze the possible role of NF-κB activation in resistance of specific 
PDA cells OV therapy. NF-κB is a transcription factor known to regulate several 
pathways of cell survival, proliferation, inflammation, angiogenesis and differentiation 
(Shishodia and Aggarwal 2002) and shown to be constitutively active in various cancers 
including PDA (Baldwin 1996) . To identify the NF-κB inhibitor which can reverse the 
VSV-∆M51-GFP resistance of PDA cells, a panel of known NF-κB inhibitors targeting 
the NF-κB activation through different pathways is being screened. In this screening 
experiment we have observed that a specific NF-κB inhibitor have increased the VSV 
replication and increased PDA cell killing. Our data demonstrated that the expression of 
specific ISGs (MxA and OAS) are at least partially responsible of VSV resistance. 
Previously, NF-κB activation has been implicated to induce specific ISGs. To determine 
the exact molecular mechanism of this NF-κB inhibitor in increasing oncolytic VSV 
replication and increased PDA cell killing, we plan to investigate the mRNA expression 
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profile of VSV resistant cells, mock treated, treated with the effective NF-κB inhibitor or 
with JAK inh. I using Affymatrix microarray. This experiment will be able to identify all 
ISGs which are constitutively expressed only in VSV resistant cells and could potentially 
be targeted to overcome this resistance. Moreover, experiments are also in progress to 
determine which of these inhibitors can down regulate MxA and OAS expression and 
simultaneously improves oncolysis. Pretreatment of this inhibitor is able to reverse the 
VSV resistance in resistant PDA cells. To show that these results can be translated in 
vivo, we have planned to test the efficacy of this effective NF-κB inhibitor in athymic 
nude mouse model system to potentially reduce tumor burden. Further, we aim to 
evaluate the expression of specific ISGs such as MxA and OAS in clinical samples from 
various pancreatic cancer patients to demonstrate the clinical significance of this study. 
VSV kill cells by inducing apoptosis and known to induce apoptosis via several 
pathways (Gaddy DF and and Lyles 2007). Many cancer cells are known to have defect 
in some of the apoptotic pathway. These defects may lead to the resistance of cancer cells 
to VSV. Another project in our laboratory is investigating the possible role of defective 
apoptotic signaling in PDA cells resistance to VSV.   
My studies demonstrated that the expression of specific ISGs, MxA and OAS 
might contribute to the VSV-ΔM51-GFP resistance in specific PDA cells. Also, 
susceptibility to VSV-ΔM51-GFP can be increased in all resistant cells, when MxA and 
OAS expression is reduced by the inhibition of Jak/STAT signaling. This information can 
be used in future to develop an assay to identify PDA cells or other cancer cells likely to 
get treated with VSV-ΔM51-GFP.  Cancer cell types showing constitutive expression of 
ISGs can be treated with alternative oncolytic viruses which are better in evading cellular 
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type I IFN response. Alternatively, treatment with more than one OV (combined 
virotherapy) could also lead to enhanced oncolysis as was previously shown for VSV in 
combination with vaccinia virus (Le Boeuf, Diallo et al. 2010). In addition, combination 
of oncolytic virus and chemotherapeutic drugs can be used to enhance oncolysis in 
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